10-Q/A

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-18-096031.txt : 20180326 0001193125-18-096031.hdr.sgml : 20180326 20180326164446 ACCESSION NUMBER: 0001193125-18-096031 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 50 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20180326 DATE AS OF CHANGE: 20180326 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RXi Pharmaceuticals Corp CENTRAL INDEX KEY: 0001533040 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36304 FILM NUMBER: 18713239 BUSINESS ADDRESS: STREET 1: 257 SIMARANO DRIVE STREET 2: SUITE 101 CITY: MARLBOROUGH STATE: MA ZIP: 01752 BUSINESS PHONE: (508) 767-3861 MAIL ADDRESS: STREET 1: 257 SIMARANO DRIVE STREET 2: SUITE 101 CITY: MARLBOROUGH STATE: MA ZIP: 01752 10-Q/A 1 d553905d10qa.htm 10-Q/A 10-Q/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q/A

Amendment No. 1

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-36304

RXi Pharmaceuticals Corporation

(Exact name of registrant as specified in its charter)

Delaware

45-3215903

(State of incorporation)

(I.R.S. Employer

Identification No.)

257 Simarano Drive, Suite 101, Marlborough, MA 01752

(Address of principal executive office) (Zip code)

Registrant’s telephone number: (508) 767-3861

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter time that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of March 15, 2018, RXi Pharmaceuticals Corporation had 2,594,962 shares of common stock, $0.0001 par value, outstanding.

EXPLANATORY NOTE

RXi Pharmaceuticals Corporation (“we,” “our,” “us” and the “Company”) is filing this Amendment No. 1 on Form 10-Q/A to amend and restate in their entirety the following items of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as originally filed with the Securities and Exchange Commission on November 8, 2017. (the “Original Form 10-Q”):

•

Part I – Item 1. Financial Statements (unaudited)

•

Part I – Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

•

Part I – Item 4. Controls and Procedures

•

Part II – Item 6. Exhibits

•

Exhibit 31.1 – Certification of Chief Executive Officer

•

Exhibit 31.2 – Certification of Chief Financial Officer

•

Exhibits 101 – Extensible Business Reporting Language (XBRL)

This amendment does not modify any disclosures contained in our original Form 10-Q, except for the foregoing Items and Exhibits, and all share and per share amounts for the periods presented to give effect to the 1-for-10 reverse stock split of the Company’s common stock, which was effected on January 8, 2018. This report on Form 10-Q/A is presented as of the filing date of the Original Form 10-Q and does not reflect events occurring after that date, or modify or update disclosures in any way other than as required to reflect the restatement described below. Accordingly, this Quarterly Report on Form 10-Q/A should be read in conjunction with the Original Form 10-Q, and the Company’s other filings with the Securities and Exchange Commission (“SEC”) subsequent to the filing of the Original Form 10-Q, including any amendments thereto.

The purpose of this amendment is to restate our previously reported results for the quarter ended September 30, 2017 to include the accounting for the tax-related impact of the Company’s acquisition of MirImmune Inc. (“MirImmune”) on January 6, 2017. Our results did not include the contemplation of deferred taxes based on the different book basis and tax basis for the acquisition of MirImmune. The acquisition resulted in an increase of $1.6 million to acquired in-process research and development expense and a corresponding $1.6 million income tax benefit resulting from the reduction in the Company’s valuation allowance due to the deferred tax liability created as a result of the book and tax basis difference, which were not accounted for properly. The condensed consolidated financial statements for the quarter ended September 30, 2017 included in this Form 10-Q/A have been restated to include this adjustment to reflect the tax-related impact of the acquisition of MirImmune. This adjustment does not affect previously reported net loss or operating cash flows, although certain adjustments have been made in our condensed consolidated statement of cash flows to correspond to the income statement adjustment as described in Note 2 of the notes to our condensed consolidated financial statements included in this filing, and has no impact on the Company’s balance sheet. We have made necessary conforming changes in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” resulting from the correction of this error.

RXi PHARMACEUTICALS CORPORATION

FORM 10-Q — QUARTER ENDED SEPTEMBER 30, 2017

INDEX


Part No.	Item No.		Description	Page No.
I			FINANCIAL INFORMATION

		1	Financial Statements (Unaudited)		4
			Condensed Consolidated Balance Sheets as of September 30, 2017 and December 31, 2016		4
			Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2017 and 2016		5
			Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2017 and 2016		6
			Notes to Condensed Consolidated Financial Statements		7
		2	Management’s Discussion and Analysis of Financial Condition and Results of Operations		13
		3	Quantitative and Qualitative Disclosures about Market Risk		19
		4	Controls and Procedures		19

II			OTHER INFORMATION		19

		1	Legal Proceedings		19
		1A	Risk Factors		19
		2	Unregistered Sales of Equity Securities and Use of Proceeds		20
		3	Defaults Upon Senior Securities		20
		4	Mine Safety Disclosures		20
		5	Other Information		20
		6	Exhibits		21
Signatures					22

PART I — FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

RXi PHARMACEUTICALS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except share and per share data)

(Unaudited)


	September 30, 2017			December 31, 2016
ASSETS
Current assets:
Cash and cash equivalents	$	5,416		$	12,906
Restricted cash		50			50
Prepaid expenses		271			150

Total current assets		5,737			13,106
Property and equipment, net		269			114
Notes receivable		—			150
Other assets		27			27

Total assets	$	6,033		$	13,397

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	702		$	917
Accrued expenses		1,901			1,625

Total current liabilities		2,603			2,542
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 authorized
Series B convertible preferred stock, par value; 8,100 shares authorized; 5,737 shares issued and outstanding at December 31, 2016		—			3,525
Series C convertible preferred stock, par value; 1,800,000 shares authorized; no shares issued or outstanding		—			—
Common stock, $0.0001 par value, 100,000,000 shares authorized; 2,369,733 and 1,300,318 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively		—			—
Additional paid-in capital		79,979			73,429
Accumulated deficit		(76,549	)		(66,099	)

Total stockholders’ equity		3,430			10,855

Total liabilities and stockholders’ equity	$	6,033		$	13,397

The accompanying notes are an integral part of these financial statements.

RXi PHARMACEUTICALS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except share and per share data)

(Unaudited)


	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Net revenues	$	—		$	—		$	—		$	19
Operating expenses:
Research and development		1,490			1,464			4,166			4,108
Acquired in-process research and development		—			—			4,696			—
General and administrative		986			752			3,209			2,587

Total operating expenses		2,476			2,216			12,071			6,695

Operating loss		(2,476	)		(2,216	)		(12,071	)		(6,676	)

Other income (expense):
Interest income, net		—			4			—			15
Other income (expense), net		—			—			—			6

Total other income		—			4			—			21

Loss before income taxes		(2,476	)		(2,212	)		(12,071	)		(6,655	)
Income tax benefit		—			—			1,621			—
Net loss	$	(2,476	)	$	(2,212	)	$	(10,450	)	$	(6,655	)

Net loss per common share:
Basic and diluted	$	(1.05	)	$	(3.36	)	$	(4.71	)	$	(10.16	)

Weighted average common shares: basic and diluted		2,351,144			657,609			2,216,775			654,869

The accompanying notes are an integral part of these financial statements.

RXi PHARMACEUTICALS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands)

(Unaudited)


	Nine Months Ended September 30,
	2017			2016
Cash flows from operating activities:
Net loss	$	(10,450	)	$	(6,655	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		48			41
Non-cash stock-based compensation		276			649
Acquired in-process research and development		4,696			—
Deferred taxes		(1,621	)		—
Value of non-marketable equity securities recognized as revenue		—			(9	)
Changes in operating assets and liabilities:
Prepaid expenses and other assets		(121	)		(10	)
Accounts payable		(417	)		(706	)
Accrued expenses		276			302

Net cash used in operating activities		(7,313	)		(6,388	)
Cash flows from investing activities:
Purchase of short-term investments		—			(2,000	)
Maturities of short-term investments		—			5,500
Cash acquired in MirImmune Inc. acquisition		100			—
Cash paid for purchase of property and equipment		(203	)		(2	)

Net cash (used in) provided by investing activities		(103	)		3,498
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of offering costs		(74	)		152

Net cash (used in) provided by financing activities		(74	)		152
Net decrease in cash, cash equivalents and restricted cash		(7,490	)		(2,738	)
Cash, cash equivalents and restricted cash at the beginning of period		12,956			5,167

Cash, cash equivalents and restricted cash at the end of period	$	5,466		$	2,429

Supplemental disclosure of non-cash investing and financing activities:
Conversions of Series B convertible preferred stock into common stock	$	3,525		$	—

Conversion of Series C convertible preferred stock into common stock	$	816		$	—

MirImmune Inc. Acquisition:
Cancellation of notes receivable	$	150		$	—

Accounts payable assumed	$	5		$	—

Fair value of securities issued	$	2,824		$	—

The accompanying notes are an integral part of these financial statements.

RXi PHARMACEUTICALS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Nature of Operations

RXi Pharmaceuticals Corporation (“RXi,” “we,” “our” or the “Company”) is a clinical-stage company developing innovative therapeutics based on our proprietary self-delivering RNAi (sd-rxRNA^®) platform and Samcyprone™ which address significant unmet medical needs. We have a pipeline of discovery, preclinical and clinical product candidates in the areas of dermatology, ophthalmology and cell-based cancer immunotherapy. The Company’s clinical development programs include RXI-109, an sd-rxRNA for the treatment of dermal and ocular scarring, and Samcyprone™, a topical immunomodulator, for the treatment of warts. The Company’s pipeline, coupled with our extensive patent portfolio, provides for product development and business development opportunities across a broad spectrum of therapeutic areas.

On January 3, 2018, the Board of Directors of the Company approved a 1-for-10 reverse stock split of the Company’s outstanding common stock, which was effected on January 8, 2018. All share and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split, including reclassifying an amount equal to the reduction in par value to additional paid-in capital.

2. Liquidity and Going Concern

The Company has limited cash resources, certain limitations under the purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”) and has expended substantial funds on the research and development of our product candidates and funding general operations. As a result, we have reported recurring losses from operations since inception and expect that we will continue to have negative cash flows from our operations for the foreseeable future. Historically, the Company’s primary source of financing has been the sale of its securities. Our ability to continue to fund our operations is dependent on the amount of cash on hand and our ability to raise additional capital through, but not limited to, equity or debt offerings or strategic opportunities. This is dependent on a number of factors, including the market demand or liquidity of our common stock. There can be no assurance that the Company will be successful in accomplishing these plans. As a result, we have concluded that there is substantial doubt regarding our ability to continue as a going concern for at least one year. If we fail to obtain additional funding when needed, we would be forced to scale back or terminate our operations or to seek to merge with or to be acquired by another company. These financial statements do not include any adjustments to, or classification of, recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

3. Significant Accounting Policies

Restatement of Consolidated Financial Statements

Our condensed consolidated statement of operations and our condensed consolidated statement of cash flows for the quarter ended September, 2017 have been restated to include the tax-related impact of the Company’s acquisition of MirImmune Inc. (“MirImmune”) on January 6, 2017. Our results did not include the contemplation of deferred taxes based on the different book basis and tax basis for the acquisition of MirImmune. The acquisition resulted in an increase to acquired in-process research and development expense and a corresponding income tax benefit resulting from the reduction in the Company’s valuation allowance due to the deferred tax liability created as a result of the book and tax basis difference. This adjustment does not affect previously reported net loss or operating cash flows, although certain adjustments have been made in our condensed consolidated statement of cash flows to correspond to the income statement adjustment as noted below. The restatement did not impact our condensed consolidated statement of operations for the three months ended September 30, 2017. The following table summarizes the effects of our restatement on the nine months ended September 30, 2017 resulting from the correction of this error.


	Nine Months Ended September 30, 2017
	Previously Reported			Adjustment			Restated
	($ in thousands, except per share data)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS:
Operating Expenses:
Research and development	$	4,166		$	—		$	4,166
Acquired in-process research and development		3,075			1,621			4,696
General and administrative		3,209			—			3,209

Total operating expenses		10,450			1,621			12,071

Operating loss		(10,450	)		(1,621	)		(12,071	)

Loss before income taxes		(10,450	)		(1,621	)		(12,071	)
Income tax benefit		—			1,621			1,621

Net loss	$	(10,450	)	$	—		$	(10,450	)

Net loss per common share: basic and diluted	$	(4.71	)	$	—		$	(4.71	)
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS:
Cash flows from operating activities:
Net loss	$	(10,450	)	$	—		$	(10,450	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization		48			—			48
Non-cash stock-based compensation		276			—			276
Acquired in-process research and development		3,075			1,621			4,696
Deferred tax		—			(1,621	)		(1,621	)
Changes in operating assets and liabilities:
Prepaid expenses and other assets		(121	)		—			(121	)
Accounts payable		(417	)		—			(417	)
Accrued expenses		276			—			276

Net cash used in operating expenses	$	(7,313	)	$	—		$	(7,313	)

Basis of Presentation

The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Certain information and footnote disclosures included in the Company’s annual financial statements have been condensed or omitted. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation of the condensed consolidated financial statements have been included. Interim results are not necessarily indicative of results for a full year.

Uses of Estimates in Preparation of Financial Statements

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid instruments with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in certificates of deposit.

Restricted cash consists of certificates of deposit held by financial institutions as collateral for the Company’s corporate credit cards.

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same such amounts shown in the statement of cash flows (in thousands):


	September 30,		December 31,
	2017		2016
Cash and cash equivalents		5,416		12,906
Restricted cash		50		50

Cash, cash equivalents and restricted cash shown in the statement of cash flows		5,466		12,956

Research and Development Expenses

Research and development costs are charged to expense as incurred and relate to salaries, employee benefits, facility-related expenses, supplies, stock-based compensation related to employees and non-employees involved in the Company’s research and development, external services, other operating costs and overhead related to our research and development departments, costs to acquire technology licenses and expenses associated with preclinical activities and our clinical trials. Payments made by the Company in advance for research and development services not yet provided and/or for materials not yet received are recorded as prepaid expenses. Accrued liabilities are recorded related to those expenses for which vendors have not yet billed us with respect to services provided and/or materials that we have received.

Preclinical and clinical trial expenses relate to third-party services, subject-related fees at the sites where our clinical trials are being conducted, laboratory costs, analysis costs, toxicology studies and investigator fees. Costs associated with these expenses are generally payable on the passage of time or when certain milestones are achieved. Expense is recorded during the period incurred or in the period in which a milestone is achieved. In order to ensure that we have adequately provided for preclinical and clinical expenses during the proper period, we maintain an accrual to cover these expenses. These accruals are assessed on a quarterly basis and are based on such assumptions as expected total cost, the number of subjects and clinical trial sites and length of the study. Actual results may differ from these estimates and could have a material impact on our reported results. Our historical accrual estimates have not been materially different from our actual costs.

Stock-based Compensation

The Company follows the provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, “Compensation — Stock Compensation” (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, officers and non-employee directors, including stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period.

For stock options granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50, “Equity Based Payments to Non-Employees.” Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the requisite service period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of these options, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the Company’s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.

Comprehensive Loss

The Company’s comprehensive loss is equal to its net loss for all periods presented.

Net Loss per Share

The Company accounts for and discloses net loss per share in accordance with FASB ASC Topic 260, “Earnings per Share.” Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted earnings per share is computed by dividing the Company’s net earnings by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares.

4. Recent Accounting Pronouncements

In August 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-15, “Statement of Cash Flows (Topic 230) — Classification of Certain Cash Receipts and Cash Payments,” which clarifies how certain cash receipts and payments are presented and classified in the statement of cash flows. This standard will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted. The amendments in ASU 2016-15 should be applied using a retrospective transition method to each period presented. The Company adopted ASU 2016-15 in the first quarter of 2017 and the implementation of this standard had no impact on the Company’s financial statements.

In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230) — Restricted Cash,” which requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash and restricted cash equivalents. With this standard, amounts generally described as restricted cash or restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning of period and end of period total amounts shown on the statement of cash flows. This standard will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted. The Company adopted ASU 2016-18 in the first quarter of 2017, and the guidance has been retrospectively applied to all periods presented. The total of cash, cash equivalents and restricted cash is described in Note 3. The adoption of the guidance did not have an impact on the Company’s balance sheet or statement of operations.

In January 2017, the FASB issued ASU 2017-01, “Business Combinations (Topic 805) — Clarifying the Definition of a Business,” which provides a screen to determine when an integrated set of assets and activities are not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. This standard will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. The Company adopted ASU 2017-01 effective January 1, 2017. The implementation of this standard did not have an impact on the Company’s financial statements as the acquisition of MirImmune Inc., (“MirImmune”), the Company’s transaction that this ASU would have affected, did not meet the definition of a business under either the prior guidance or the new guidance.

In May 2017, the FASB issued ASU 2017-09, “Compensation — Stock Compensation (Topic 718) — Scope of Modification Accounting,” which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. This standard will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted. The Company adopted ASU 2017-09 in the second quarter of 2017, and the implementation of this standard had no impact on the Company’s financial statements.

5. MirImmune Inc. Acquisition

On January 6, 2017, the Company entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) and completed its acquisition of MirImmune. Subject to the terms of the Stock Purchase Agreement, RXi Merger Sub, LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company (“RXi Merger Sub”), was merged with and into MirImmune, with RXi Merger Sub continuing as the surviving entity and changing its name to “MirImmune, LLC”. As a result of the merger, MirImmune, LLC remains and operates as a wholly-owned subsidiary of the Company. Pursuant to the Stock Purchase Agreement, the Company acquired all of the issued and outstanding shares of capital stock of MirImmune for an aggregate of 275,036 shares of common stock of the Company and an aggregate of 1,118,224 shares of Series C Convertible Preferred Stock of the Company (the “Series C Convertible Preferred Stock”). The shares of common stock and Series C Convertible Preferred Stock were subject to a holdback of 3% of the aggregate closing consideration for any purchase price adjustments. The shares subject to the holdback, adjusted for post-closing items, were released and issued on April 12, 2017.

Upon the closing of the acquisition, the notes receivable outstanding on the Company’s balance sheet as of December 31, 2016 were cancelled.

The Company assessed the acquisition of MirImmune under FASB ASC Topic 805, “Business Combinations” (“ASC 805”). Under ASC 805, the Company determined that the acquired assets did not constitute a business and that the transaction would be accounted for as an asset acquisition. The assets and development programs acquired from MirImmune are at an early stage of development and will require a significant investment of time and capital if we are to be successful in developing them. There is no assurance that we will be successful in developing such assets, and a failure to successfully develop such assets could diminish our prospects. Under ASC 805, the assets acquired are considered to have no alternative future uses, as determining the future economic benefit of the acquired assets at the date of acquisition is highly uncertain. The fair value of the assets was determined using the quoted market price of the Company’s common stock on January 6, 2017, the date of the acquisition, and fully expensed as in-process research and development.

Additionally, the Company assessed the MirImmune acquisition under ASC Topic 740, “Income Taxes” (“ASC 740”). The acquisition resulted in an income tax benefit of $1,621,000 and a corresponding increase to acquired in-process research and development expense resulting from the reduction in the Company’s valuation allowance due to the deferred tax liability created as a result of the book and tax basis difference.

During the nine months ended September 30, 2017, the Company recorded $4,696,000 in in-process research and development expense related to the fair value of consideration given, which includes transaction costs, liabilities assumed and cancellation of notes receivable, and the deferred tax impact of the MirImmune acquisition.

The Company was restricted from converting any of the Series C Convertible Preferred Stock into common stock to the extent that such conversion was not approved by the Company’s stockholders in accordance with the stockholder approval requirements of NASDAQ Marketplace Rule 5635. On June 9, 2017, with the approval of the Company’s stockholders in accordance with the NASDAQ stockholder approval requirements, every ten shares of the Series C Convertible Preferred Stock outstanding were automatically converted into one share of common stock, such that there were no shares of Series C Convertible Preferred Stock issued or outstanding at September 30, 2017. On November 7, 2017, the Company filed a Certificate Eliminating the Series C Convertible Preferred Stock from the Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware. Please refer to Note 10 for further discussion of the filing.

Under the terms of the Stock Purchase Agreement, if certain development or commercial milestones are achieved within two years, the Company will be required to either (i) issue a number of shares of common stock (the “Milestone Shares”) equal to the sum of 251,909 shares of common stock, plus an additional number of shares of common stock equal to 13% of the common stock issued upon exercise of any warrants issued under the Company’s underwritten public offering in December 2016, but only to the extent that such warrants have been exercised prior to the milestone being achieved or (ii) pay the equivalent value of the Milestone Shares in cash. The Company received shareholder approval in accordance with Rule 5635 of the NASDAQ Marketplace Rules at its 2017 Annual Meeting of Stockholders to issue any shares in satisfaction of the achievement of the milestones.

The Company assessed the Milestone Shares under FASB ASC Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”). The Company determined that liability accounting would be required for the Milestone Shares under ASC 480. The Company will record a liability related to the Milestone Shares if and when the milestones are achieved and the consideration becomes payable. At that time, the Company will record the cost of the Milestone Shares as in-process research and development expense. No milestones have been met as of September 30, 2017.

6. Fair Value Measurements

The Company follows the provisions of FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” for the Company’s financial assets and liabilities that are re-measured and reported at fair value at each reporting period and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:

Level 1 — quoted prices in active markets for identical assets or liabilities.

Level 2 — other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

Level 3 — significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

The warrant issued to the Company by Thera Neuropharma, Inc. (“Thera”) is categorized as Level 3 hierarchy. The estimated fair value inputs utilizing the asset-based approach for the warrant issued to the Company by Thera include the stage of enterprise development, terms of existing contractual arrangements of the entity’s equity securities, the achievement of milestones and other unobservable inputs.

Financial assets measured at fair value on a recurring basis are summarized as follows, in thousands:


Description	At September 30, 2017		Quoted Prices in Active Markets (Level 1)		Other Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Warrant in Thera	$	5	$	—	$	—	$	5

Total	$	5	$	—	$	—	$	5


Description	At December 31, 2016		Quoted Prices in Active Markets (Level 1)		Other Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Warrant in Thera	$	5	$	—	$	—	$	5

Total	$	5	$	—	$	—	$	5

A reconciliation of the beginning and ending Level 3 assets for the nine months ended September 30, 2017 is as follows (in thousands):


	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, beginning of period	$	5
Change in value of the warrant in Thera		—

Balance, end of period	$	5

Fair Value of Financial Instruments

The carrying amounts reported in the balance sheet for cash equivalents, restricted cash and accounts payable approximate their fair values due to their short-term nature.

7. Stockholders’ Equity

Series B Convertible Preferred Stock — The Company’s remaining shares of Series B Convertible Preferred Stock (“Series B Convertible Preferred Stock”) outstanding at December 31, 2016 were fully converted into 637,445 shares of common stock of the Company during the first quarter of 2017, such that there are no shares of Series B Convertible Preferred Stock issued or outstanding at September 30, 2017. On November 7, 2017, the Company filed a Certificate Eliminating the Series B Convertible Preferred Stock from the Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware. Please refer to Note 10 for further discussion of the filing.

Series C Convertible Preferred Stock — In connection with the Stock Purchase Agreement, on January 5, 2017, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the “Series C Convertible Preferred Stock Certificate of Designation”) with the Secretary of State of the State of Delaware. The Series C Convertible Preferred Stock Certificate of Designation provides for the issuance of up to 1,800,000 shares of Series C Convertible Preferred Stock. The Series C Convertible Preferred Stock have no voting rights, with certain exceptions as described in the Series C Convertible Preferred Stock Certificate of Designations, and shall receive dividends on an as-converted basis at the same time and in the same form as any dividends paid out on shares of the Company’s common stock. Other than as set forth in the previous sentence, no other dividends shall be paid on the Series C Convertible Preferred Stock. The Company has never paid dividends on its common stock and presently has no intention of paying dividends.

Upon its issuance, the Series C Convertible Preferred Stock was assessed under ASC 480. The Company determined that the Series C Convertible Preferred Stock was not within the scope of ASC 480 and therefore, the Series C Convertible Preferred Stock was not considered a liability. The Series C Convertible Preferred Stock was recorded in permanent equity on the Company’s balance sheet.

The Series C Convertible Preferred Stock was then assessed under FASB ASC 815, “Derivatives and Hedging” (“ASC 815”). The Company believes that the Series C Convertible Preferred Stock is an equity host for the purposes of assessing the embedded conversion option for potential bifurcation. The Company concluded that the conversion option feature is clearly and closely related to the preferred stock host. As such, the conversion feature did not require bifurcation under ASC 815.

Pursuant to the Stock Purchase Agreement, the Company acquired all of the issued and outstanding shares of capital stock of MirImmune for an aggregate of 275,036 shares of common stock of the Company and an aggregate of 1,118,224 shares of Series C Convertible Preferred Stock. The Company was restricted from converting any of the Series C Convertible Preferred Stock into common stock to the extent that such conversion was not approved by the Company’s stockholders in accordance with the stockholder approval requirements of NASDAQ Marketplace Rule 5635. On June 9, 2017, with the approval of the Company’s stockholders in accordance with the NASDAQ stockholder approval requirements, every ten shares of the Series C Convertible Preferred Stock outstanding were automatically converted into one share of common stock, such that there were no shares of Series C Convertible Preferred Stock issued or outstanding at September 30, 2017. Please refer to Notes 5 and 10 for further details on the shares issued in connection with the acquisition of MirImmune.

has the right to sell to LPC up to $15,000,000 in shares of the Company’s common stock, subject to certain limitations and conditions set forth in the 2017 Purchase Agreement. As a commitment fee for entering into the 2017 Purchase Agreement, the Company issued to LPC 45,000 shares of Company common stock (the “Commitment Shares”). The Commitment Shares had a value per share of $5.80 and were recorded as a cost of capital. The Company intends to use the net proceeds from the 2017 Purchase Agreement for working capital and general corporate purposes. There have been no purchases under the 2017 Purchase Agreement as of September 30, 2017.

Warrants — The following table summarizes the Company’s outstanding warrants at September 30, 2017:


Exercise prices	Number of Shares Underlying Warrants		Expiration
$52.00		130,007		June 2, 2020
$9.00		1,277,993		December 21, 2021

Total warrants outstanding		1,408,000

During the second quarter of 2017, outstanding warrants for the purchase of 46 shares of the Company’s common stock with an exercise price of $390.00 expired.

No warrants were exercised during the nine months ended September 30, 2017 or 2016.

8. Stock-based Compensation

The Company uses the Black-Scholes option-pricing model to determine the fair value of all its option grants. For valuing options granted during the three and nine months ended September 30, 2017 and 2016, the following assumptions were used:


	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2017			2016			2017			2016
Risk-free interest rate		1.94 – 2.35	%		1.46	%		1.73 – 2.49	%		1.18 – 2.02	%
Expected volatility		83.87 – 91.99	%		116.88	%		82.99 – 123.01	%		79.42 – 116.88	%
Weighted average expected volatility		87.93	%		116.88	%		84.65	%		89.12	%
Expected lives (in years)		6.25 – 10.00			10.00			5.20 – 10.00			5.20 – 10.00
Expected dividend yield		0.00	%		0.00	%		0.00	%		0.00	%

The weighted average fair value of options granted during the three months ended September 30, 2017 and 2016 was $4.90 and $22.70, respectively. The weighted average fair value of options granted during the nine months ended September 30, 2017 and 2016 was $4.90 and $21.50, respectively.

The risk-free interest rate used for each grant was based upon the yield on zero-coupon U.S. Treasury securities with a term similar to the expected life of the related option. The Company’s expected stock price volatility assumption is based upon the volatility of a composition of comparable companies. The expected life assumption for employee grants was based upon the simplified method provided for under ASC 718, and the expected life assumption for non-employees was based upon the contractual term of the option. The dividend yield assumption of zero is based upon the fact that the Company has never paid cash dividends and presently has no intention of paying cash dividends.

The following table summarizes the activity of Company’s stock option plan for the nine months ended September 30, 2017:


	Total Number of Shares			Weighted-Average Exercise Price Per Share		Aggregate Intrinsic Value
Balance at December 31, 2016		37,444		$	272.90
Granted		33,038			6.90
Exercised		—			—
Cancelled		(17,382	)		44.80

Balance at September 30, 2017		53,100		$	182.00	$	—

Exercisable at September 30, 2017		35,495		$	262.10	$	—

The Company recorded stock-based compensation expense for the three and nine months ended September 30, 2017 and 2016 as follows, in thousands:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Research and development	$	7	$	52	$	80	$	212
General and administrative		36		76		196		437

Total stock-based compensation	$	43	$	128	$	276	$	649

Stock-based compensation expense for the nine months ended September 30, 2017 includes $22,000, recorded in research and development expense, related to stock option modifications in connection with the retirement of the Company’s former Chief Development Officer.

9. Net Loss per Share

The following table sets forth the potential common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:


	September 30,
	2017		2016
Options to purchase common stock		53,100		39,096
Warrants to purchase common stock		1,408,000		130,046

Total		1,461,100		169,142

10. Subsequent Events

On November 7, 2017, the Company filed a Certificate Eliminating the Series B Convertible Preferred Stock from the Certificate of Incorporation of the Company and a Certificate Eliminating the Series C Convertible Preferred Stock from the Certificate of Incorporation of the Company (together, the “Certificates of Elimination”) with the Secretary of State of the State of Delaware, in order to eliminate from the Certificate of Incorporation all matters set forth in the Certificate of Incorporation, including the related certificates of designation, relating to the previously issued Series B Convertible Preferred Stock and Series C Convertible Preferred Stock. As a result, the 8,100 shares of unissued Series B Convertible Preferred Stock and 1,800,000 shares of unissued Series C Convertible Preferred Stock were returned to the status of authorized but unissued shares of preferred stock of the Company, without designation as to series or preferences or rights. The foregoing summary of the Certificates of Elimination is qualified in its entirety by reference to the full text of the Certificates of Elimination, which are attached hereto as Exhibits 3.1 and 3.2 to this Quarterly Report on Form 10-Q and incorporated herein by reference.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

In this document, “we,” “our,” “ours,” “us,” “RXi” and the “Company” refers to RXi Pharmaceuticals Corporation and our subsidiary, MirImmune, LLC and the ongoing business operations of RXi Pharmaceuticals Corporation and MirImmune, LLC, whether conducted through RXi Pharmaceuticals Corporation or MirImmune, LLC.

This management’s discussion and analysis of financial condition as of September 30, 2017 and results of operations for the three and nine months ended September 30, 2017 and 2016 should be read in conjunction with the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2016 which was filed with the SEC on March 30, 2017.

This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “intends,” “believes,” “anticipates,” “indicates,” “plans,” “expects,” “suggests,” “may,” “should,” “potential,” “designed to,” “will” and similar references. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone™ and our other product candidates (collectively, “our

product candidates”); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; the future success of our strategic partnerships; and our ability to implement cost-saving measures. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others: the risk that our clinical trials with our product candidates may not be successful in evaluating the safety and tolerability of these candidates or providing evidence of increased surgical scar reduction compared to placebo or clearance of common warts; the successful and timely completion of clinical trials; uncertainties regarding the regulatory process; the availability of funds and resources to pursue our research and development projects, including our clinical trials with our product candidates; general economic conditions; and those identified in our Annual Report on Form 10-K for the year ended December 31, 2016 under the heading “Risk Factors” and in other filings the Company periodically makes with the Securities and Exchange Commission. Forward-looking statements contained in this Quarterly Report on Form 10-Q speak as of the date hereof and the Company does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this report.

Overview

RNAi therapies are designed to “silence,” or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. The Company’s first RNAi clinical product candidate, RXI-109, is a self-delivering RNAi compound (sd-rxRNA) that commenced human clinical trials in 2012. RXI-109 is designed to reduce the expression of connective tissue growth factor (“CTGF”), a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. RXI-109 is currently being evaluated in a Phase 2 clinical trial, Study 1402, to prevent or reduce dermal scarring following scar revision surgery of an existing hypertrophic scar and a Phase 1/2 clinical trial, Study 1501, to evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring in subjects with wet age-related macular degeneration (“AMD”).

Study 1402, the Company’s Phase 2 clinical trial in hypertrophic scars, commenced in July 2014. In October 2015, we reported that preliminary data from Study 1402 demonstrated that scars at revision sites were judged to be better at three months after a treatment regimen with five mg/cm intradermal administration of RXI-109 than scars at untreated revision sites in those same subjects. Based in part on this new information, two more cohorts (Cohorts 3 and 4) were added to Study 1402 in November 2015. For these two cohorts, the number of doses was increased to either eight or nine doses of RXI-109 over a six-month period to better cover the extended wound healing/scarring profile of hypertrophic scars. Enrollment of subjects into these two new cohorts completed ahead of schedule during the third quarter of 2016.

In December 2016, the Company announced that preliminary data from the first two cohorts from Study 1402 at nine months confirmed the positive differentiation by a blinded panel of observers from untreated surgery incisions in hypertrophic scars from the previously presented data for a subset of subjects treated with five mg/cm of RXI-109 at three months. In addition, this data extends this observation to all time points, including the post-treatment follow-up period through nine months post-surgery. RXI-109 was safe and well tolerated. Additionally, as expected, the limited three-month data available from Cohort 3 appeared to align with that of the first two cohorts as these subjects all had the same dosing schedule through the third month. A complete read-out of the whole study, including all four cohorts with follow-up until nine months post-surgery, is expected by the end of 2017.

Study 1501, the Company’s Phase 1/2 clinical trial in retinal scars, commenced in November 2015, and is a multi-dose, dose escalation study conducted in subjects with AMD with evidence of subretinal fibrosis. Each subject receives four doses of RXI-109 by intraocular injection at one month intervals for a total dosing period of three months. The safety and tolerability of RXI-109, as well as the potential for clinical activity, is evaluated over the course of the study using numerous assessments to monitor the health of the retina and to assess visual acuity. To date, there have been no safety issues that have precluded continuation of dosing. Study 1501 has been completely enrolled, dosing in the third cohort at the highest planned dose level is completed and patient follow-up is ongoing. The Company expects to complete subject participation in the study by the end of 2017 and to share top-line data in early 2018.

Samcyprone™, the Company’s second clinical candidate, is a proprietary topical formulation of the small molecule diphenylcyclopropenone (“DPCP”), an immunomodulator that works by initiating a T-cell response. The use of Samcyprone™ allows sensitization using much lower concentrations of DPCP than are used with existing compounded DPCP solutions, avoiding hyper-sensitization to subsequent challenge doses. Samcyprone™ is currently being evaluated in a Phase 2a clinical trial, Study 1502, for the clearance of common warts.

Study 1502 was initiated in December 2015. Study 1502 includes a sensitization phase in which a spot on the subject’s upper arm and one or more warts are treated with Samcyprone™. After being sensitized in this way, the subjects enter into the treatment phase where up to four warts are treated on a once weekly basis for ten weeks with a ten-fold lower concentration of Samcyprone™ than in the sensitization phase. During the trial, the warts are scored, photographed and measured to monitor the level of clearance.

In December 2016, the Company announced the results from a preliminary review of sensitization and wart clearance data from a subset of subjects that have completed the ten-week treatment phase of Study 1502. Results showed that greater than 90% of the subjects demonstrated a sensitization response, a prerequisite to be able to develop a therapeutic response. Additionally, more than 60% of the subjects responded to the treatment by exhibiting either complete or greater than 50% clearance of all treated warts with up to ten weekly treatments. Samcyprone^™ treatment has been generally safe and well tolerated and has had drug-related adverse events relating to local reactions, which are typically expected for this type of treatment due to the sensitization and challenge responses in the skin. The Company added a second cohort, which was fully enrolled in September 2017, to Study 1502 to explore the opportunity to reduce the sensitization dose level, which will be more convenient to physicians and subjects. Early read-outs of the study are anticipated by the end of 2017.

In addition to our clinical programs, we continue to advance our preclinical and discovery programs with our sd-rxRNA technology. RXI-231, our lead sd-rxRNA compound targeting tyrosinase (“TYR”), is in cosmetic development as a cosmetic ingredient that may improve the appearance of uneven skin tone and pigmentation. Cosmetics are compounds that affect the appearance of the skin and make no preventative or therapeutic claims. These compounds may be developed more rapidly than therapeutics, therefore the path to market may be much shorter and less expensive. Efficacy and toxicity testing in cell culture and skin equivalents for RXI-231 has been successfully completed and human testing of RXI-231 commenced in June 2017 with a U.S. clinical testing site. The Company has completed irritation and sensitization studies with RXI-231, the first two of three studies planned. Early results from the irritation and sensitization studies demonstrated that RXI-231 is not a skin irritant, and it does not cause allergic contact dermatitis. The third study investigates the potential of RXI-231 to improve the appearance of skin pigmentation induced by UV exposure and is ongoing. Full reports from these studies are expected before the end of 2017.

On January 6, 2017, the Company entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) by and among the Company, RXi Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“RXi Merger Sub”), MirImmune Inc. (“MirImmune”), the stockholders of MirImmune set forth on the signature pages thereto (each a “Seller” and collectively, the “Sellers”), and Alexey Wolfson, Ph.D., in his capacity as the Sellers’ Representative. Pursuant to the Stock Purchase Agreement, the Company acquired from the Sellers all of the issued and outstanding shares of capital stock of MirImmune for an aggregate of 275,036 shares of common stock of the Company and an aggregate of 1,118,224 shares of Series C Convertible Preferred Stock of the Company (the “Series C Convertible Preferred Stock”). On June 9, 2017, with the approval of the Company’s stockholders in accordance with the stockholder approval requirements of Nasdaq Marketplace Rule 5635, every ten shares of Series C Convertible Preferred Stock outstanding were automatically converted into one share of common stock, such that no shares of Series C Convertible Preferred Stock remained issued or outstanding. On November 7, 2017, the Company filed a Certificate Eliminating the Series C Convertible Preferred Stock from the Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware. Please refer to Part II, Item 5 of this quarterly report on Form 10-Q for further discussion of the filing.

In connection with and promptly following the closing of the Stock Purchase Agreement, MirImmune was merged with and into RXi Merger Sub (the “Merger”), with RXi Merger Sub continuing as the surviving entity and changing its name to “MirImmune, LLC”. As a result of the Merger, MirImmune, LLC remains and operates as a wholly-owned subsidiary of the Company.

Building on the work completed by MirImmune prior to its acquisition by the Company, our cell-based cancer immunotherapy program with sd-rxRNA includes lead compounds for a number of immune checkpoint targets that provide long lasting immune checkpoint silencing, individually and in combination, in adoptively transferred cells. An improved efficacy upon the silencing of checkpoints has been demonstrated in various types of adoptively transferred cells relevant in cancer immunotherapy, such as CAR T-cells and tumor infiltrating lymphocytes (TILs). The Company’s ongoing discovery programs include, but are not limited to, the evaluation of sd-rxRNA compounds to impact the differentiation of various immune effector cells. The Company has also initiated in vivo evaluations of multiple checkpoint inhibiting sd-rxRNA compounds co-transfected in CAR T-cells in mouse models for solid tumors, with data from these studies expected by the end of 2017.

Additionally, the Company recently selected two sd-rxRNA compounds from its immunotherapy pipeline for preclinical development. For oncology treatments based on adoptive cell transfer (ACT), compounds RXI-762 and RXI-804 suppress the expression of immune checkpoint proteins PD-1 and TIGIT, respectively, which can result in an improved efficacy to the targeted tumors. This decision triggered the selection of a manufacturing facility to initiate production of cGMP grade material, initially for RXI-762. This also supports moving RXI-762 into clinical development as early as 2018 as part of an ACT therapy.

On August 8, 2017, the Company entered into a purchase agreement (the “2017 Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“LPC”), pursuant to which the Company has the right to sell to LPC up to $15,000,000 in shares of the Company’s common stock, subject to certain limitations and conditions set forth therein, over the 30-month term of the 2017 Purchase Agreement.

Since inception, we have incurred significant losses. Substantially all of our losses to date have resulted from research and development expenses in connection with our clinical and research programs and from general and administrative costs. At September 30, 2017, we had an accumulated deficit of $76.5 million. We expect to continue to incur significant losses for the foreseeable future, particularly as we advance our development programs for RXI-109 and Samcyprone™ and expand our program in cell-based cancer immunotherapy.

Critical Accounting Policies and Estimates

There have been no significant changes to our critical accounting policies since the beginning of this fiscal year. Our critical accounting policies are described in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our Annual Report on Form 10-K for the year ended December 31, 2016, which we filed with the SEC on March 30, 2017.

Results of Operations

The following data summarizes the results of our operations for the periods indicated, in thousands:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Net revenues	$	—		$	—		$	—		$	19
Operating expenses		(2,476	)		(2,216	)		(12,071	)		(6,695	)
Operating loss		(2,476	)		(2,216	)		(12,071	)		(6,676	)
Income tax benefit		—			—			1,621			—
Net loss		(2,476	)		(2,212	)		(10,450	)		(6,655	)

Comparison of the Three and Nine Months Ended September 30, 2017 and 2016

Net Revenues

To date, we have primarily generated revenues through government grants. The following table summarizes our total net revenues, for the periods indicated, in thousands:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Net revenues	$	—	$	—	$	—	$	19

The Company did not have net revenues for the three and nine months ended September 30, 2017 and the three months ended September 30, 2016.

Net revenues were approximately $19,000 for the nine months ended September 30, 2016, which related to the Company’s exclusive license agreements with Thera Neuropharma, Inc. and MirImmune, prior to its acquisition by the Company.

Operating Expenses

The following table summarizes our total operating expenses, for the periods indicated, in thousands:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Research and development	$	1,490	$	1,464	$	4,166	$	4,108
Acquired in-process research and development		—		—		4,696		—
General and administrative		986		752		3,209		2,587

Total operating expenses	$	2,476	$	2,216	$	12,071	$	6,695

Research and Development Expenses

Research and development expenses consist of compensation-related costs for our employees dedicated to research and development activities, fees related to our Scientific Advisory Board members, expenses related to our ongoing research and development efforts primarily related to our clinical trials, drug manufacturing, outside contract services, licensing and patent fees and laboratory supplies and services for our research programs.

Research and development expenses were $1,490,000 for the three months ended September 30, 2017, compared with $1,464,000 for the three months ended September 30, 2016. The increase of $26,000, or 2%, was due to an increase of $71,000 in research and development expenses primarily driven by subject fees for the second cohort in the Samcyprone™ Phase 2 clinical trial and preclinical work in the Company’s new immunotherapy program that was integrated into the Company with the acquisition of MirImmune in the first quarter of 2017, offset by a decrease of $45,000 in stock-based compensation expense.

Research and development expenses were $4,166,000 for the nine months ended September 30, 2017, compared with $4,108,000 for the nine months ended September 30, 2016. The increase of $58,000, or 1%, was due to an increase of $190,000 in research and development expenses primarily driven by work in the Company’s new immunotherapy program that commenced in the first quarter of 2017, offset by a decrease of $132,000 in stock-based compensation expense.

Acquired In-process Research and Development Expense

In January 2017, the Company acquired all of the issued and outstanding capital stock of MirImmune, a privately-held biotechnology company that was engaged in the development of cancer immunotherapies, in exchange for securities of the Company. During the nine months ended September 30, 2017, the Company recorded $4,696,000 in in-process research and development expense related to the fair value of consideration given, which includes transaction costs, liabilities assumed and cancellation of notes receivable, and the deferred tax impact of the MirImmune acquisition. The Company did not have acquired in-process research and development expense for the three and nine months ended September 30, 2016 and the three months ended September 30, 2017.

General and Administrative Expenses

General and administrative expenses consist primarily of compensation-related costs for our employees dedicated to general and administrative activities, legal fees, audit and tax fees, consulting fees, professional service fees and general corporate expenses.

General and administrative expenses were $986,000 for the three months ended September 30, 2017, compared with $752,000 for the three months ended September 30, 2016. The increase of $234,000, or 31%, was due to an increase of $274,000 in general and administrative expenses primarily due to payroll-related expenses, including severance benefits, with the hire of the Company’s former chief business officer in connection with the acquisition of MirImmune, resulting in a higher employee headcount as compared to the same period of the prior year, offset by a decrease of $40,000 in stock-based compensation expense.

General and administrative expenses were $3,209,000 for the nine months ended September 30, 2017, compared with $2,587,000 for the nine months ended September 30, 2016. The increase of $622,000, or 24%, was due to an increase of $863,000 in general and administrative expenses primarily due to payroll-related expenses, including severance benefits, with the hire of the Company’s former chief business officer in connection with the acquisition of MirImmune, resulting in a higher employee headcount as compared to the same period of the prior year, and legal fees and accounting-related expenses. These increases were offset by a decrease of $241,000 in stock-based compensation expense.

Income Tax

The following table summarizes the Company’s income tax for the periods indicated, in thousands:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Income tax benefit	$	—	$	—	$	1,621	$	—

For the nine months ended September 30, 2017, we recognized an income tax benefit of $1,621,000 for the tax-related impact of the Company’s acquisition of MirImmune Inc. on January 6, 2017. There was no income tax expense or benefit during the three months ended September 30, 2017 and the three months and nine months ended September 30, 2016.

Liquidity and Capital Resources

On December 18, 2014, the Company entered into a purchase agreement (the “2014 Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“LPC”), pursuant to which the Company had the right to sell to LPC up to $10.8 million in shares of the Company’s common stock, subject to certain limitations and conditions set forth in the 2014 Purchase Agreement. The 2014 Purchase Agreement expired on April 17, 2017. Under the 2014 Purchase Agreement, the Company sold a total of 7,000 shares of common stock to LPC for net proceeds of approximately $216,000.

On December 21, 2016, the Company closed an underwritten public offering (the “Offering”) of (i) 379,777 Class A Units, at a public offering price of $9.00 per unit, consisting of one share of the Company’s common stock and a five-year warrant to purchase one share of common stock at an exercise price of $9.00 per share (the “Warrants”) and (ii) 8,082 Class B Units, at a public offering price of $1,000 per unit, consisting of one share of Series B Convertible Preferred Stock (the “Series B Convertible Preferred Stock”), which was convertible into 111.11 shares of common stock, and 111.11 Warrants. The Class A Units include an additional 166,667 Class A Units pursuant to the exercise by the underwriters of their over-allotment option. The total net proceeds of the Offering, including the exercise of the over-allotment option, were $10,051,000 after deducting underwriting discounts and commissions and offering expenses paid by the Company.

On August 8, 2017, the Company entered into the 2017 Purchase Agreement with LPC, pursuant to which the Company has the right to sell to LPC up to $15,000,000 in shares of the Company’s common stock, subject to certain limitations and conditions set forth therein, over the 30-month term of the 2017 Purchase Agreement. As a commitment fee for entering into the 2017 Purchase Agreement, the Company issued to LPC 45,000 shares of Company common stock at a value per share of $5.80. As of September 30, 2017, there have been no purchases under the 2017 Purchase Agreement.

We had cash of $5.4 million as of September 30, 2017, compared with cash of $12.9 million as of December 31, 2016. Based on the Company’s cash, operational spending rate, and limitations under the 2017 Purchase Agreement, the Company has concluded that there is substantial doubt regarding our ability to fund the Company’s operations for at least the next twelve months. We have generated significant losses to date, have not generated any product revenue to date and may not generate product revenue in the foreseeable future, or ever. We expect to incur significant operating losses as we advance our product candidates through drug development and the regulatory process. In the future, we will be dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity, funded research and development programs and payments under partnership and collaborative research and business development agreements, in order to maintain our operations and meet our obligations to licensors. There is no guarantee that debt, additional equity or other funding will be available to us on acceptable terms, or at all. If we fail to obtain additional funding when needed, we would be forced to scale back or terminate our operations or to seek to merge with or to be acquired by another company.

The following table summarizes our cash flows for the periods indicated, in thousands:


	Nine Months Ended September 30,
	2017			2016
Net cash used in operating activities	$	(7,313	)	$	(6,388	)
Net cash (used in) provided by investing activities		(103	)		3,498
Net cash (used in) provided by financing activities		(74	)		152

Net decrease in cash, cash equivalents and restricted cash	$	(7,490	)	$	(2,738	)

Net Cash Flow from Operating Activities

Net cash used in operating activities was $7,313,000 for the nine months ended September 30, 2017, compared with $6,388,000 for the nine months ended September 30, 2016. The increase in cash used in operating activities was primarily due to an increase in net loss of $3,795,000, offset by changes in non-cash expenses of $2,718,000 mainly driven by in-process research and development expense related to the fair value of consideration given and the tax-related impact resulting from the acquisition of MirImmune in January 2017.

Net Cash Flow from Investing Activities

Net cash used in investing activities was $103,000 for the nine months ended September 30, 2017, compared with net cash provided by investing activities of $3,498,000 for the nine months ended September 30, 2016. The decrease in net cash flow from investing activities was primarily related to the purchase of laboratory equipment in the current year as compared with maturities of short-term investments in the prior year.

Net Cash Flow from Financing Activities

Net cash used in financing activities was $74,000 for the nine months ended September 30, 2017, compared with net cash provided by financing activities of $152,000 for the nine months ended September 30, 2016. The decrease in net cash flow from financing activities was due to net proceeds received from the issuance of common stock as compared with the same period in the prior year.

Off-Balance Sheet Arrangements

In connection with certain license agreements, we are required to indemnify the licensor for certain damages arising in connection with the intellectual property rights licensed under the agreement. In addition, we are a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate us to indemnify the other parties to such agreements upon the occurrence of certain events. These indemnification obligations are considered off-balance sheet arrangements in accordance with ASC Topic 460, “Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others.” To date, we have not encountered material costs as a result of such obligations and have not accrued any liabilities related to such obligations in our financial statements. See Note 8 to our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2016, which was filed with the SEC on March 30, 2017, for further discussion of these indemnification agreements.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and acting Chief Financial Officer, evaluated the effectiveness of disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2017, the end of the period covered by our Original Form 10-Q. Based on that evaluation, our Chief Executive Officer and acting Chief Financial Officer concluded that our disclosure controls and procedures were effective to ensure that information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms.

Subsequently, in connection with the preparation of our Annual Report on Form 10-K, our management, with the participation of our Chief Executive Officer and acting Chief Financial Officer, reassessed the effectiveness of the Company’s internal control over financial reporting. In connection with this assessment, we identified a material weakness, as described below, in our internal control over financial reporting as of September 30, 2017. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. Because of the material weakness, identified below, management concluded that, as of September 30, 2017, our disclosure controls and procedures were not effective.

Inadequate and ineffective controls over accounting for income taxes

We did not have adequate design or operation of controls that provide reasonable assurance on a timely basis that the accounting for income taxes, including the related financial statement disclosures, were in accordance with U.S. generally accepted accounting principles. On an annual basis, we engage and rely upon third-party tax accountants to provide technical expertise with respect to complex tax accounting matters to assist us in maintaining adequate controls that provide reasonable assurance as to the complete and accurate recording and disclosure of deferred taxes due to differences in accounting treatment for book and tax purposes and other tax-related matters in our financial statements.

Our previously reported results prior to this amendment did not include the contemplation of deferred taxes based on the different book basis and tax basis for the acquisition of MirImmune. The acquisition resulted in an increase of $1.6 million to acquired in-process research and development expense and a corresponding $1.6 million income tax benefit resulting from the reduction in the Company’s valuation allowance due to the deferred tax liability created as a result of the book and tax basis difference, which were not accounted for properly. Our condensed consolidated financial statements for the quarter ended September 30, 2017 included in this Form 10-Q/A have been restated to include this adjustment to reflect the tax-related impact of the acquisition of MirImmune. This adjustment did not affect previously reported net loss or operating cash flows and had no impact on the Company’s balance sheet.

Remediation Plans

Management is committed to remediating the material weakness in a timely fashion. We have begun the process of executing remediation plans that address the material weakness in internal control over financial reporting relating to accounting for income taxes. Management’s planned actions to address the material weakness include:

•

Increased involvement on a quarterly basis of our third-party tax accountants dedicated to determining the appropriate accounting for material and complex tax transactions in a timely manner;

•

Review of tax accounting process to identify and implement enhanced tax accounting processes and related internal control procedures; and

•

Establishing additional training and education programs for financial personnel responsible for income tax accounting.

Under the direction of the Audit Committee, management will continue to review and make necessary changes to the overall design of the Company’s internal control environment, as well as policies and procedures to improve the overall effectiveness of internal control over financial reporting.

Management believes the measures described above that will be implemented will remediate the control deficiencies identified and will strengthen our internal control over financial reporting. We continuously seek to improve and strengthen our control processes to ensure that all of our controls and procedures are adequate and effective. As management continues to evaluate and work to improve internal control over financial reporting, we may take additional measures to address control deficiencies or determine to modify, or in appropriate circumstances not to complete, certain of the remediation measures described above.

Changes in Internal Control over Financial Reporting

There has not been any change in our internal control over financial reporting that occurred during the quarterly period ended September 30, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

None.

ITEM 1A.

RISK FACTORS

You should consider the “Risk Factors” included under Item 1A. of our Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC on March 30, 2017.

We may not be able to regain compliance with the continued listing requirements of The Nasdaq Capital Market.

On February 2, 2017, we received written notice (the “Notification Letter”) from the Nasdaq Stock Market (“Nasdaq”) notifying us that we are not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of our common stock for the 30 consecutive business days prior to the date of the Notification Letter, we no longer meet the minimum bid price requirement. The Notification Letter provided an initial 180-day period to regain compliance, which was extended for a second 180-day period on August 2, 2017. As a result of the extension, we have until January 29, 2018 to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. In the event that we do not regain compliance by that date, Nasdaq may commence delisting proceedings and our common stock will trade, if at all, on the over-the counter market, such as the OTC Bulletin Board or OTCQX market, which could adversely impact us by, among other things, reducing the liquidity and market price of our common stock; reducing the number of investors willing to hold or acquire our common stock; limiting our ability to issue additional securities in the future; and limiting our ability to fund our operations.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.

OTHER INFORMATION

ITEM 6.

EXHIBITS

EXHIBIT INDEX


Exhibit Number		Incorporated by Reference Herein
Exhibit Number	Description	Form		Date

3.1	Certificate Eliminating the Series B Convertible Preferred Stock from the Certificate of Incorporation of RXi Pharmaceuticals Corporation*		Quarterly Report on Form 10-Q (File No. 001-36304)		November 8, 2017

3.2	Certificate Eliminating the Series C Convertible Preferred Stock from the Certificate of Incorporation of RXi Pharmaceuticals Corporation*		Quarterly Report on Form 10-Q (File No. 001-36304)		November 8, 2017

10.1	Purchase Agreement, dated August 8, 2017, between RXi Pharmaceuticals Corporation and Lincoln Park Capital Fund, LLC		Registration Statement on Form S-1 (File No. 333-220062)		August 18, 2017

31.1	Sarbanes-Oxley Act Section 302 Certification of Chief Executive Officer and Chief Financial Officer.*

32.1	Sarbanes-Oxley Act Section 906 Certification of Chief Executive Officer and Chief Financial Officer.*

101	The following financial information from the Quarterly Report on Form 10-Q of RXi Pharmaceuticals Corporation for the quarter ended September 30, 2017, formatted in XBRL (eXtensible Business Reporting Language): (1) Condensed Consolidated Balance Sheets as of September 30, 2017 and December 31, 2016; (2) Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2017 and 2016; (3) Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2017 and 2016; and (4) Notes to Condensed Consolidated Financial Statements (Unaudited).*

*	Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


RXi Pharmaceuticals Corporation

By:		/s/ Geert Cauwenbergh
		Geert Cauwenbergh, Dr. Med. Sc.
		President, Chief Executive Officer and acting Chief Financial Officer

		Date: March 26, 2018

EX-31.1 2 d553905dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Geert Cauwenbergh, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q/A of RXi Pharmaceuticals Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Dated: March 26, 2018

/s/ Geert Cauwenbergh

Geert Cauwenbergh, Dr. Med. Sc.

President, Chief Executive Officer and acting Chief Financial Officer

(as Principal Executive and Financial Officer)

EX-32.1 3 d553905dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of RXi Pharmaceuticals Corporation (the “Company”) on Form 10-Q/A for the period ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the Company’s financial condition and result of operations.

/s/ Geert Cauwenbergh

Geert Cauwenbergh, Dr. Med. Sc.

President, Chief Executive Officer and acting Chief
Financial Officer

(as Principal Executive and Financial Officer)

March 26, 2018

EX-101.INS 4 rxii-20170930.xml XBRL INSTANCE DOCUMENT 15000000

5.80

8100

1800000

2594962

2429000

390.00

1901000

5737000

79979000

702000

6033000

5416000

100000000

2369733

1408000

0.0001

2369733

6033000

2603000

27000

0.0001

10000000

271000

269000

50000

-76549000

35495

262.10

53100

182.00

3430000

5466000

5000

8100

1800000

9.00

1277993

52.00

130007

5167000

1625000

13106000

73429000

917000

13397000

12906000

100000000

1300318

0.0001

1300318

13397000

2542000

150000

27000

0.0001

10000000

150000

114000

50000

-66099000

37444

272.90

10855000

12956000

5000

8100

3525000

5737

1800000

45000

275036

0.03

1118224

0.13 251909

0.001

Company approved a 1-for-10 reverse stock split of the Company's outstanding common stock, which was effected on January 8, 2018.

true RXi Pharmaceuticals Corporation (“we,” “our,” “us” and the “Company”) is filing this Amendment No. 1 on Form 10-Q/A to amend and restate in their entirety the following items of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as originally filed with the Securities and Exchange Commission on November 8, 2017. (the “Original Form 10-Q”):•Part I - Item 1. Financial Statements (unaudited)•Part I - Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations•Part I - Item 4. Controls and Procedures• Part II - Item 6. Exhibits • Exhibit 31.1 - Certification of Chief Executive Officer• Exhibit 31.2 - Certification of Chief Financial Officer • Exhibits 101 - Extensible Business Reporting Language (XBRL) This amendment does not modify any disclosures contained in our original Form 10-Q, except for the foregoing Items and Exhibits, and all share and per share amounts for the periods presented to give effect to the 1-for-10 reverse stock split of the Company’s common stock, which was effected on January 8, 2018. This report on Form 10-Q/A is presented as of the filing date of the Original Form 10-Q and does not reflect events occurring after that date, or modify or update disclosures in any way other than as required to reflect the restatement described below. Accordingly, this Quarterly Report on Form 10-Q/A should be read in conjunction with the Original Form 10-Q, and the Company’s other filings with the Securities and Exchange Commission (“SEC”) subsequent to the filing of the Original Form 10-Q, including any amendments thereto.The purpose of this amendment is to restate our previously reported results for the quarter ended September 30, 2017 to include the accounting for the tax-related impact of the Company’s acquisition of MirImmune Inc. (“MirImmune”) on January 6, 2017. Our results did not include the contemplation of deferred taxes based on the different book basis and tax basis for the acquisition of MirImmune. The acquisition resulted in an increase of $1.6 million to acquired in-process research and development expense and a corresponding $1.6 million income tax benefit resulting from the reduction in the company's vluation allowance due to the deferred tax liability created as a result of the book and tax basis difference, which were not accounted for properly. The condensed consolidated financial statements for the quarter ended September 30, 2017 included in this Form 10-Q/A have been restated to include this adjustment to reflect the tax-related impact of the acquisition of MirImmune. This adjustment does not affect previously reported net loss or operating cash flows, although certain adjustments have been made in our condensed consolidated statement of cash flows to correspond to the income statement adjustment as described in Note 2 of the notes to our condensed consolidated financial statements included in this filing, and has no impact on the company's balance sheet. We have made necessary conforming changes in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” resulting from the correction of this error.

1461100

<div> Basis of Presentation The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Certain information and footnote disclosures included in the Company’s annual financial statements have been condensed or omitted. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation of the condensed consolidated financial statements have been included. Interim results are not necessarily indicative of results for a full year. </div>

<div> Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid instruments with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in certificates of deposit. Restricted cash consists of certificates of deposit held by financial institutions as collateral for the Company’s corporate credit cards.   The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same such amounts shown in the statement of cash flows (in thousands):   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="73%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">December 31,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Cash and cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,416</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,906</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Restricted cash </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Cash, cash equivalents and restricted cash shown in the statement of cash flows </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,466</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,956</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

100000

<div> Comprehensive Loss The Company’s comprehensive loss is equal to its net loss for all periods presented. </div>

--12-31

-1621000

48000

-4.71

<div> 9. Net Loss per Share The following table sets forth the potential common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="78%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">September 30,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Options to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">53,100</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">39,096</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Warrants to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,408,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">130,046</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,461,100</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">169,142</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> 8. Stock-based Compensation The Company uses the Black-Scholes option-pricing model to determine the fair value of all its option grants. For valuing options granted during the three and nine months ended September 30, 2017 and 2016, the following assumptions were used:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="52%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> For the Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> For the Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.94 – 2.35</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.46</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.73 – 2.49</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.18 – 2.02</td> <td nowrap="nowrap" valign="bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right"> 83.87 – 91.99</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">116.88</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right"> 82.99 – 123.01</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right"> 79.42 – 116.88</td> <td nowrap="nowrap" valign="bottom">% </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Weighted average expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">87.93</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">116.88</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">84.65</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">89.12</td> <td nowrap="nowrap" valign="bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expected lives (in years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.25 – 10.00</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10.00</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.20 – 10.00</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.20 – 10.00</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.00</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.00</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.00</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.00</td> <td nowrap="nowrap" valign="bottom">% </td> </tr> </table> The weighted average fair value of options granted during the three months ended September 30, 2017 and 2016 was $4.90 and $22.70, respectively. The weighted average fair value of options granted during the nine months ended September 30, 2017 and 2016 was $4.90 and $21.50, respectively. The risk-free interest rate used for each grant was based upon the yield on zero-coupon U.S. Treasury securities with a term similar to the expected life of the related option. The Company’s expected stock price volatility assumption is based upon the volatility of a composition of comparable companies. The expected life assumption for employee grants was based upon the simplified method provided for under ASC 718, and the expected life assumption for non-employees was based upon the contractual term of the option. The dividend yield assumption of zero is based upon the fact that the Company has never paid cash dividends and presently has no intention of paying cash dividends. The following table summarizes the activity of Company’s stock option plan for the nine months ended September 30, 2017:   <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="62%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Total Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Weighted-Average Exercise Price Per Share</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Balance at December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,444</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">272.90</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,038</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.90</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td nowrap="nowrap" valign="bottom"> </td> <td nowrap="nowrap" valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td nowrap="nowrap" valign="bottom"> </td> <td nowrap="nowrap" valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(17,382</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44.80</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Balance at September 30, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">53,100</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">182.00</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td nowrap="nowrap" valign="bottom">$</td> <td nowrap="nowrap" valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Exercisable at September 30, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">35,495</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">262.10</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td nowrap="nowrap" valign="bottom">$</td> <td nowrap="nowrap" valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   The Company recorded stock-based compensation expense for the three and nine months ended September 30, 2017 and 2016 as follows, in thousands:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="73%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">52</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">80</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">212</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">36</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">76</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">196</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">437</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total stock-based compensation </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">43</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">128</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">276</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">649</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Stock-based compensation expense for the nine months ended September 30, 2017 includes $22,000, recorded in research and development expense, related to stock option modifications in connection with the retirement of the Company’s former Chief Development Officer. </div>

Q3 2017 10-Q/A

<div> Net Loss per Share The Company accounts for and discloses net loss per share in accordance with FASB ASC Topic 260, “Earnings per Share.” Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted earnings per share is computed by dividing the Company’s net earnings by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares. </div>

2017-09-30

<div> Financial assets measured at fair value on a recurring basis are summarized as follows, in thousands:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="44%"></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom" nowrap="nowrap"> Description </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">At September 30, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Quoted Prices in Active Markets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Other Significant Observable Inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Warrant in Thera </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom" nowrap="nowrap"> Description </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">At December 31, 2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Quoted Prices in Active Markets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Other Significant Observable Inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Warrant in Thera </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

RXi Pharmaceuticals Corp

<div> A reconciliation of the beginning and ending Level 3 assets for the nine months ended September 30, 2017 is as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="21%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance, beginning of period </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Change in value of the warrant in Thera </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance, end of period </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> 6. Fair Value Measurements The Company follows the provisions of FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” for the Company’s financial assets and liabilities that are re-measured and reported at fair value at each reporting period and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows: Level 1 — quoted prices in active markets for identical assets or liabilities. Level 2 — other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date. Level 3 — significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date. The warrant issued to the Company by Thera Neuropharma, Inc. (“Thera”) is categorized as Level 3 hierarchy. The estimated fair value inputs utilizing the asset-based approach for the warrant issued to the Company by Thera include the stage of enterprise development, terms of existing contractual arrangements of the entity’s equity securities, the achievement of milestones and other unobservable inputs. Financial assets measured at fair value on a recurring basis are summarized as follows, in thousands:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="44%"></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom" nowrap="nowrap"> Description </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">At September 30, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Quoted Prices in Active Markets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Other Significant Observable Inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Warrant in Thera </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom" nowrap="nowrap"> Description </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">At December 31, 2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Quoted Prices in Active Markets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Other Significant Observable Inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Warrant in Thera </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   A reconciliation of the beginning and ending Level 3 assets for the nine months ended September 30, 2017 is as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="21%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance, beginning of period </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Change in value of the warrant in Thera </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance, end of period </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Fair Value of Financial Instruments The carrying amounts reported in the balance sheet for cash equivalents, restricted cash and accounts payable approximate their fair values due to their short-term nature. </div>

0001533040 Smaller Reporting Company

2824000

3209000

-12071000

276000

-1621000

-417000

121000

Three months or less

<div> 1. Nature of Operations RXi Pharmaceuticals Corporation (“RXi,” “we,” “our” or the “Company”) is a clinical-stage company developing innovative therapeutics based on our proprietary self-delivering RNAi (sd-rxRNA®) platform and Samcyprone™ which address significant unmet medical needs. We have a pipeline of discovery, preclinical and clinical product candidates in the areas of dermatology, ophthalmology and cell-based cancer immunotherapy. The Company’s clinical development programs include RXI-109, an sd-rxRNA for the treatment of dermal and ocular scarring, and Samcyprone™, a topical immunomodulator, for the treatment of warts. The Company’s pipeline, coupled with our extensive patent portfolio, provides for product development and business development opportunities across a broad spectrum of therapeutic areas. On January 3, 2018, the Board of Directors of the Company approved a 1-for-10 reverse stock split of the Company’s outstanding common stock, which was effected on January 8, 2018. All share and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split, including reclassifying an amount equal to the reduction in par value to additional paid-in capital. </div>

-103000

-7313000

<div> 4. Recent Accounting Pronouncements In August 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-15, “Statement of Cash Flows (Topic 230) — Classification of Certain Cash Receipts and Cash Payments,” which clarifies how certain cash receipts and payments are presented and classified in the statement of cash flows. This standard will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted. The amendments in ASU 2016-15 should be applied using a retrospective transition method to each period presented. The Company adopted ASU 2016-15 in the first quarter of 2017 and the implementation of this standard had no impact on the Company’s financial statements. In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230) — Restricted Cash,” which requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash and restricted cash equivalents. With this standard, amounts generally described as restricted cash or restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning of period and end of period total amounts shown on the statement of cash flows. This standard will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted. The Company adopted ASU 2016-18 in the first quarter of 2017, and the guidance has been retrospectively applied to all periods presented. The total of cash, cash equivalents and restricted cash is described in Note 3. The adoption of the guidance did not have an impact on the Company’s balance sheet or statement of operations. In January 2017, the FASB issued ASU 2017-01, “Business Combinations (Topic 805) — Clarifying the Definition of a Business,” which provides a screen to determine when an integrated set of assets and activities are not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. This standard will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. The Company adopted ASU 2017-01 effective January 1, 2017. The implementation of this standard did not have an impact on the Company’s financial statements as the acquisition of MirImmune Inc., (“MirImmune”), the Company’s transaction that this ASU would have affected, did not meet the definition of a business under either the prior guidance or the new guidance. In May 2017, the FASB issued ASU 2017-09, “Compensation — Stock Compensation (Topic 718) — Scope of Modification Accounting,” which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. This standard will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted. The Company adopted ASU 2017-09 in the second quarter of 2017, and the implementation of this standard had no impact on the Company’s financial statements. </div>

12071000

-74000

-10450000

5000

-12071000

150000

203000

<div> Restatement of Consolidated Financial Statements Our condensed consolidated statement of operations and our condensed consolidated statement of cash flows for the quarter ended September, 2017 have been restated to include the tax-related impact of the Company’s acquisition of MirImmune Inc. (“MirImmune”) on January 6, 2017. Our results did not include the contemplation of deferred taxes based on the different book basis and tax basis for the acquisition of MirImmune. The acquisition resulted in an increase to acquired in-process research and development expense and a corresponding income tax benefit resulting from the reduction in the Company’s valuation allowance due to the deferred tax liability created as a result of the book and tax basis difference. This adjustment does not affect previously reported net loss or operating cash flows, although certain adjustments have been made in our condensed consolidated statement of cash flows to correspond to the income statement adjustment as noted below. The restatement did not impact our condensed consolidated statement of operations for the three months ended September 30, 2017. The following table summarizes the effects of our restatement on the nine months ended September 30, 2017 resulting from the correction of this error.   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">Nine Months Ended September 30, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Previously Reported</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Adjustment</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Restated</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="10" align="center"> ($ in thousands, except per share data)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS: </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Operating Expenses: </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,166</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,166</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Acquired in-process research and development </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,075</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,621</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,696</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> General and administrative </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,209</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,209</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total operating expenses </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,450</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,621</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,071</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating loss </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(10,450</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,621</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(12,071</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Loss before income taxes </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(10,450</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,621</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(12,071</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Income tax benefit </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,621</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,621</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net loss </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(10,450</td> <td valign="bottom" nowrap="nowrap">)</td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(10,450</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net loss per common share: basic and diluted </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(4.71</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(4.71</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS: </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cash flows from operating activities: </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net loss </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(10,450</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(10,450</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Adjustments to reconcile net loss to net cash used in operating activities </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">48</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">48</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Non-cash stock-based compensation </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">276</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">276</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Acquired in-process research and development </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,075</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,621</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,696</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Deferred tax </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,621</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,621</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Changes in operating assets and liabilities: </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Prepaid expenses and other assets </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(121</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(121</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts payable </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(417</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(417</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accrued expenses </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">276</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">276</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net cash used in operating expenses </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(7,313</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(7,313</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-74000

4696000

4166000

<div> Research and Development Expenses Research and development costs are charged to expense as incurred and relate to salaries, employee benefits, facility-related expenses, supplies, stock-based compensation related to employees and non-employees involved in the Company’s research and development, external services, other operating costs and overhead related to our research and development departments, costs to acquire technology licenses and expenses associated with preclinical activities and our clinical trials. Payments made by the Company in advance for research and development services not yet provided and/or for materials not yet received are recorded as prepaid expenses. Accrued liabilities are recorded related to those expenses for which vendors have not yet billed us with respect to services provided and/or materials that we have received. Preclinical and clinical trial expenses relate to third-party services, subject-related fees at the sites where our clinical trials are being conducted, laboratory costs, analysis costs, toxicology studies and investigator fees. Costs associated with these expenses are generally payable on the passage of time or when certain milestones are achieved. Expense is recorded during the period incurred or in the period in which a milestone is achieved. In order to ensure that we have adequately provided for preclinical and clinical expenses during the proper period, we maintain an accrual to cover these expenses. These accruals are assessed on a quarterly basis and are based on such assumptions as expected total cost, the number of subjects and clinical trial sites and length of the study. Actual results may differ from these estimates and could have a material impact on our reported results. Our historical accrual estimates have not been materially different from our actual costs. </div>

<div> The following table sets forth the potential common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="78%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">September 30,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Options to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">53,100</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">39,096</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Warrants to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,408,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">130,046</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,461,100</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">169,142</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The Company recorded stock-based compensation expense for the three and nine months ended September 30, 2017 and 2016 as follows, in thousands:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="73%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">52</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">80</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">212</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">36</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">76</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">196</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">437</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total stock-based compensation </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">43</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">128</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">276</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">649</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The following table summarizes the effects of our restatement on the nine months ended September 30, 2017 resulting from the correction of this error.   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">Nine Months Ended September 30, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Previously Reported</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Adjustment</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Restated</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="10" align="center"> ($ in thousands, except per share data)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS: </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Operating Expenses: </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,166</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,166</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Acquired in-process research and development </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,075</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,621</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,696</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> General and administrative </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,209</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,209</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total operating expenses </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,450</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,621</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,071</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating loss </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(10,450</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,621</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(12,071</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Loss before income taxes </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(10,450</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,621</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(12,071</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Income tax benefit </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,621</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,621</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net loss </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(10,450</td> <td valign="bottom" nowrap="nowrap">)</td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(10,450</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net loss per common share: basic and diluted </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(4.71</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(4.71</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS: </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cash flows from operating activities: </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net loss </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(10,450</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(10,450</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Adjustments to reconcile net loss to net cash used in operating activities </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">48</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">48</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Non-cash stock-based compensation </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">276</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">276</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Acquired in-process research and development </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,075</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,621</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,696</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Deferred tax </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,621</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,621</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Changes in operating assets and liabilities: </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Prepaid expenses and other assets </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(121</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(121</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts payable </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(417</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(417</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accrued expenses </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">276</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">276</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net cash used in operating expenses </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(7,313</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(7,313</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The following table summarizes the activity of Company’s stock option plan for the nine months ended September 30, 2017:   <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="62%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Total Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Weighted-Average Exercise Price Per Share</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Balance at December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,444</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">272.90</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,038</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.90</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td nowrap="nowrap" valign="bottom"> </td> <td nowrap="nowrap" valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td nowrap="nowrap" valign="bottom"> </td> <td nowrap="nowrap" valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(17,382</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44.80</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Balance at September 30, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">53,100</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">182.00</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td nowrap="nowrap" valign="bottom">$</td> <td nowrap="nowrap" valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Exercisable at September 30, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">35,495</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">262.10</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td nowrap="nowrap" valign="bottom">$</td> <td nowrap="nowrap" valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The Company uses the Black-Scholes option-pricing model to determine the fair value of all its option grants. For valuing options granted during the three and nine months ended September 30, 2017 and 2016, the following assumptions were used:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="52%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> For the Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> For the Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.94 – 2.35</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.46</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.73 – 2.49</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.18 – 2.02</td> <td nowrap="nowrap" valign="bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right"> 83.87 – 91.99</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">116.88</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right"> 82.99 – 123.01</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right"> 79.42 – 116.88</td> <td nowrap="nowrap" valign="bottom">% </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Weighted average expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">87.93</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">116.88</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">84.65</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">89.12</td> <td nowrap="nowrap" valign="bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expected lives (in years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.25 – 10.00</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10.00</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.20 – 10.00</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.20 – 10.00</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.00</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.00</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.00</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.00</td> <td nowrap="nowrap" valign="bottom">% </td> </tr> </table> </div>

<div>  The following table summarizes the Company’s outstanding warrants at September 30, 2017:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="59%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom" nowrap="nowrap"> Exercise prices </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Shares Underlying Warrants</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Expiration</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> $52.00 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">130,007</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">June 2, 2020</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> $9.00 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,277,993</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">December 21, 2021</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total warrants outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,408,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div>

276000

1.2301

17382

44.80

0.0000

0.8299

0.0173

4.90

6.90

<div> Stock-based Compensation The Company follows the provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, “Compensation — Stock Compensation” (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, officers and non-employee directors, including stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period. For stock options granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50, “Equity Based Payments to Non-Employees.” Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the requisite service period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of these options, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the Company’s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested. </div>

0.8465

22000

0.0249

33038

<div> 7. Stockholders’ Equity Series B Convertible Preferred Stock — The Company’s remaining shares of Series B Convertible Preferred Stock (“Series B Convertible Preferred Stock”) outstanding at December 31, 2016 were fully converted into 637,445 shares of common stock of the Company during the first quarter of 2017, such that there are no shares of Series B Convertible Preferred Stock issued or outstanding at September 30, 2017. On November 7, 2017, the Company filed a Certificate Eliminating the Series B Convertible Preferred Stock from the Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware. Please refer to Note 10 for further discussion of the filing. Series C Convertible Preferred Stock — In connection with the Stock Purchase Agreement, on January 5, 2017, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the “Series C Convertible Preferred Stock Certificate of Designation”) with the Secretary of State of the State of Delaware. The Series C Convertible Preferred Stock Certificate of Designation provides for the issuance of up to 1,800,000 shares of Series C Convertible Preferred Stock. The Series C Convertible Preferred Stock have no voting rights, with certain exceptions as described in the Series C Convertible Preferred Stock Certificate of Designations, and shall receive dividends on an as-converted basis at the same time and in the same form as any dividends paid out on shares of the Company’s common stock. Other than as set forth in the previous sentence, no other dividends shall be paid on the Series C Convertible Preferred Stock. The Company has never paid dividends on its common stock and presently has no intention of paying dividends. Upon its issuance, the Series C Convertible Preferred Stock was assessed under ASC 480. The Company determined that the Series C Convertible Preferred Stock was not within the scope of ASC 480 and therefore, the Series C Convertible Preferred Stock was not considered a liability. The Series C Convertible Preferred Stock was recorded in permanent equity on the Company’s balance sheet. The Series C Convertible Preferred Stock was then assessed under FASB ASC 815, “Derivatives and Hedging” (“ASC 815”). The Company believes that the Series C Convertible Preferred Stock is an equity host for the purposes of assessing the embedded conversion option for potential bifurcation. The Company concluded that the conversion option feature is clearly and closely related to the preferred stock host. As such, the conversion feature did not require bifurcation under ASC 815. Pursuant to the Stock Purchase Agreement, the Company acquired all of the issued and outstanding shares of capital stock of MirImmune for an aggregate of 275,036 shares of common stock of the Company and an aggregate of 1,118,224 shares of Series C Convertible Preferred Stock. The Company was restricted from converting any of the Series C Convertible Preferred Stock into common stock to the extent that such conversion was not approved by the Company’s stockholders in accordance with the stockholder approval requirements of NASDAQ Marketplace Rule 5635. On June 9, 2017, with the approval of the Company’s stockholders in accordance with the NASDAQ stockholder approval requirements, every ten shares of the Series C Convertible Preferred Stock outstanding were automatically converted into one share of common stock, such that there were no shares of Series C Convertible Preferred Stock issued or outstanding at September 30, 2017. Please refer to Notes 5 and 10 for further details on the shares issued in connection with the acquisition of MirImmune. Lincoln Park Capital Fund, LLC — On August 8, 2017, the Company entered into a purchase agreement (the “2017 Purchase Agreement”) and a registration rights agreement with LPC, pursuant to which the Company has the right to sell to LPC up to $15,000,000 in shares of the Company’s common stock, subject to certain limitations and conditions set forth in the 2017 Purchase Agreement. As a commitment fee for entering into the 2017 Purchase Agreement, the Company issued to LPC 45,000 shares of Company common stock (the “Commitment Shares”). The Commitment Shares had a value per share of $5.80 and were recorded as a cost of capital. The Company intends to use the net proceeds from the 2017 Purchase Agreement for working capital and general corporate purposes. There have been no purchases under the 2017 Purchase Agreement as of September 30, 2017. Warrants — The following table summarizes the Company’s outstanding warrants at September 30, 2017:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="59%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom" nowrap="nowrap"> Exercise prices </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Shares Underlying Warrants</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Expiration</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> $52.00 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">130,007</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">June 2, 2020</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> $9.00 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,277,993</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">December 21, 2021</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total warrants outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,408,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> During the second quarter of 2017, outstanding warrants for the purchase of 46 shares of the Company’s common stock with an exercise price of $390.00 expired. No warrants were exercised during the nine months ended September 30, 2017 or 2016. </div>

<div> 3. Significant Accounting Policies Restatement of Consolidated Financial Statements Our condensed consolidated statement of operations and our condensed consolidated statement of cash flows for the quarter ended September, 2017 have been restated to include the tax-related impact of the Company’s acquisition of MirImmune Inc. (“MirImmune”) on January 6, 2017. Our results did not include the contemplation of deferred taxes based on the different book basis and tax basis for the acquisition of MirImmune. The acquisition resulted in an increase to acquired in-process research and development expense and a corresponding income tax benefit resulting from the reduction in the Company’s valuation allowance due to the deferred tax liability created as a result of the book and tax basis difference. This adjustment does not affect previously reported net loss or operating cash flows, although certain adjustments have been made in our condensed consolidated statement of cash flows to correspond to the income statement adjustment as noted below. The restatement did not impact our condensed consolidated statement of operations for the three months ended September 30, 2017. The following table summarizes the effects of our restatement on the nine months ended September 30, 2017 resulting from the correction of this error.   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">Nine Months Ended September 30, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Previously Reported</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Adjustment</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Restated</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="10" align="center"> ($ in thousands, except per share data)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS: </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Operating Expenses: </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,166</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,166</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Acquired in-process research and development </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,075</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,621</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,696</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> General and administrative </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,209</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,209</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total operating expenses </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,450</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,621</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,071</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating loss </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(10,450</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,621</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(12,071</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Loss before income taxes </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(10,450</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,621</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(12,071</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Income tax benefit </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,621</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,621</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net loss </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(10,450</td> <td valign="bottom" nowrap="nowrap">)</td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(10,450</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net loss per common share: basic and diluted </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(4.71</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(4.71</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS: </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cash flows from operating activities: </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net loss </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(10,450</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(10,450</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Adjustments to reconcile net loss to net cash used in operating activities </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">48</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">48</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Non-cash stock-based compensation </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">276</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">276</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Acquired in-process research and development </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,075</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,621</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,696</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Deferred tax </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,621</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,621</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Changes in operating assets and liabilities: </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Prepaid expenses and other assets </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(121</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(121</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts payable </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(417</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(417</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accrued expenses </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">276</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">276</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net cash used in operating expenses </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(7,313</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(7,313</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Basis of Presentation The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Certain information and footnote disclosures included in the Company’s annual financial statements have been condensed or omitted. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation of the condensed consolidated financial statements have been included. Interim results are not necessarily indicative of results for a full year. Uses of Estimates in Preparation of Financial Statements The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid instruments with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in certificates of deposit. Restricted cash consists of certificates of deposit held by financial institutions as collateral for the Company’s corporate credit cards.   The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same such amounts shown in the statement of cash flows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cash and cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,416</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,906</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Restricted cash </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cash, cash equivalents and restricted cash shown in the statement of cash flows </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,466</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,956</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Research and Development Expenses Research and development costs are charged to expense as incurred and relate to salaries, employee benefits, facility-related expenses, supplies, stock-based compensation related to employees and non-employees involved in the Company’s research and development, external services, other operating costs and overhead related to our research and development departments, costs to acquire technology licenses and expenses associated with preclinical activities and our clinical trials. Payments made by the Company in advance for research and development services not yet provided and/or for materials not yet received are recorded as prepaid expenses. Accrued liabilities are recorded related to those expenses for which vendors have not yet billed us with respect to services provided and/or materials that we have received. Preclinical and clinical trial expenses relate to third-party services, subject-related fees at the sites where our clinical trials are being conducted, laboratory costs, analysis costs, toxicology studies and investigator fees. Costs associated with these expenses are generally payable on the passage of time or when certain milestones are achieved. Expense is recorded during the period incurred or in the period in which a milestone is achieved. In order to ensure that we have adequately provided for preclinical and clinical expenses during the proper period, we maintain an accrual to cover these expenses. These accruals are assessed on a quarterly basis and are based on such assumptions as expected total cost, the number of subjects and clinical trial sites and length of the study. Actual results may differ from these estimates and could have a material impact on our reported results. Our historical accrual estimates have not been materially different from our actual costs. Stock-based Compensation The Company follows the provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, “Compensation — Stock Compensation” (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, officers and non-employee directors, including stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period. For stock options granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50, “Equity Based Payments to Non-Employees.” Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the requisite service period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of these options, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the Company’s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested. Comprehensive Loss The Company’s comprehensive loss is equal to its net loss for all periods presented. Net Loss per Share The Company accounts for and discloses net loss per share in accordance with FASB ASC Topic 260, “Earnings per Share.” Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted earnings per share is computed by dividing the Company’s net earnings by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares. </div>

275036

<div> 2. Liquidity and Going Concern The Company has limited cash resources, certain limitations under the purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”) and has expended substantial funds on the research and development of our product candidates and funding general operations. As a result, we have reported recurring losses from operations since inception and expect that we will continue to have negative cash flows from our operations for the foreseeable future. Historically, the Company’s primary source of financing has been the sale of its securities. Our ability to continue to fund our operations is dependent on the amount of cash on hand and our ability to raise additional capital through, but not limited to, equity or debt offerings or strategic opportunities. This is dependent on a number of factors, including the market demand or liquidity of our common stock. There can be no assurance that the Company will be successful in accomplishing these plans. As a result, we have concluded that there is substantial doubt regarding our ability to continue as a going concern for at least one year. If we fail to obtain additional funding when needed, we would be forced to scale back or terminate our operations or to seek to merge with or to be acquired by another company. These financial statements do not include any adjustments to, or classification of, recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. </div>

<div> 10. Subsequent Events On November 7, 2017, the Company filed a Certificate Eliminating the Series B Convertible Preferred Stock from the Certificate of Incorporation of the Company and a Certificate Eliminating the Series C Convertible Preferred Stock from the Certificate of Incorporation of the Company (together, the “Certificates of Elimination”) with the Secretary of State of the State of Delaware, in order to eliminate from the Certificate of Incorporation all matters set forth in the Certificate of Incorporation, including the related certificates of designation, relating to the previously issued Series B Convertible Preferred Stock and Series C Convertible Preferred Stock. As a result, the 8,100 shares of unissued Series B Convertible Preferred Stock and 1,800,000 shares of unissued Series C Convertible Preferred Stock were returned to the status of authorized but unissued shares of preferred stock of the Company, without designation as to series or preferences or rights. The foregoing summary of the Certificates of Elimination is qualified in its entirety by reference to the full text of the Certificates of Elimination, which are attached hereto as Exhibits 3.1 and 3.2 to this Quarterly Report on Form 10-Q and incorporated herein by reference. </div>

RXII

2216775

<div> Uses of Estimates in Preparation of Financial Statements The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. </div>

-7490000 <div> The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same such amounts shown in the statement of cash flows (in thousands):   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="73%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">December 31,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Cash and cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,416</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,906</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Restricted cash </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Cash, cash equivalents and restricted cash shown in the statement of cash flows </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,466</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,956</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> 5. MirImmune Inc. Acquisition On January 6, 2017, the Company entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) and completed its acquisition of MirImmune. Subject to the terms of the Stock Purchase Agreement, RXi Merger Sub, LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company (“RXi Merger Sub”), was merged with and into MirImmune, with RXi Merger Sub continuing as the surviving entity and changing its name to “MirImmune, LLC”. As a result of the merger, MirImmune, LLC remains and operates as a wholly-owned subsidiary of the Company. Pursuant to the Stock Purchase Agreement, the Company acquired all of the issued and outstanding shares of capital stock of MirImmune for an aggregate of 275,036 shares of common stock of the Company and an aggregate of 1,118,224 shares of Series C Convertible Preferred Stock of the Company (the “Series C Convertible Preferred Stock”). The shares of common stock and Series C Convertible Preferred Stock were subject to a holdback of 3% of the aggregate closing consideration for any purchase price adjustments. The shares subject to the holdback, adjusted for post-closing items, were released and issued on April 12, 2017. Upon the closing of the acquisition, the notes receivable outstanding on the Company’s balance sheet as of December 31, 2016 were cancelled. The Company assessed the acquisition of MirImmune under FASB ASC Topic 805, “Business Combinations” (“ASC 805”). Under ASC 805, the Company determined that the acquired assets did not constitute a business and that the transaction would be accounted for as an asset acquisition. The assets and development programs acquired from MirImmune are at an early stage of development and will require a significant investment of time and capital if we are to be successful in developing them. There is no assurance that we will be successful in developing such assets, and a failure to successfully develop such assets could diminish our prospects. Under ASC 805, the assets acquired are considered to have no alternative future uses, as determining the future economic benefit of the acquired assets at the date of acquisition is highly uncertain. The fair value of the assets was determined using the quoted market price of the Company’s common stock on January 6, 2017, the date of the acquisition, and fully expensed as in-process research and development. Additionally, the Company assessed the MirImmune acquisition under ASC Topic 740, “Income Taxes” (“ASC 740”). The acquisition resulted in an income tax benefit of $1,621,000 and a corresponding increase to acquired in-process research and development expense resulting from the reduction in the Company’s valuation allowance due to the deferred tax liability created as a result of the book and tax basis difference. During the nine months ended September 30, 2017, the Company recorded $4,696,000 in in-process research and development expense related to the fair value of consideration given, which includes transaction costs, liabilities assumed and cancellation of notes receivable, and the deferred tax impact of the MirImmune acquisition.   The Company was restricted from converting any of the Series C Convertible Preferred Stock into common stock to the extent that such conversion was not approved by the Company’s stockholders in accordance with the stockholder approval requirements of NASDAQ Marketplace Rule 5635. On June 9, 2017, with the approval of the Company’s stockholders in accordance with the NASDAQ stockholder approval requirements, every ten shares of the Series C Convertible Preferred Stock outstanding were automatically converted into one share of common stock, such that there were no shares of Series C Convertible Preferred Stock issued or outstanding at September 30, 2017. On November 7, 2017, the Company filed a Certificate Eliminating the Series C Convertible Preferred Stock from the Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware. Please refer to Note 10 for further discussion of the filing. Under the terms of the Stock Purchase Agreement, if certain development or commercial milestones are achieved within two years, the Company will be required to either (i) issue a number of shares of common stock (the “Milestone Shares”) equal to the sum of 251,909 shares of common stock, plus an additional number of shares of common stock equal to 13% of the common stock issued upon exercise of any warrants issued under the Company’s underwritten public offering in December 2016, but only to the extent that such warrants have been exercised prior to the milestone being achieved or (ii) pay the equivalent value of the Milestone Shares in cash. The Company received shareholder approval in accordance with Rule 5635 of the NASDAQ Marketplace Rules at its 2017 Annual Meeting of Stockholders to issue any shares in satisfaction of the achievement of the milestones. The Company assessed the Milestone Shares under FASB ASC Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”). The Company determined that liability accounting would be required for the Milestone Shares under ASC 480. The Company will record a liability related to the Milestone Shares if and when the milestones are achieved and the consideration becomes payable. At that time, the Company will record the cost of the Milestone Shares as in-process research and development expense. No milestones have been met as of September 30, 2017. </div>

53100

1408000

80000

196000

P10Y

P5Y2M12D

3525000

816000

No voting rights, with certain exceptions

1118224

2021-12-21 2020-06-02

-1621000

1621000

-1621000

1621000

48000

-4.71

3209000

-10450000

276000

-417000

121000

-7313000

10450000

-10450000

3075000

4166000

276000

169142

41000

-10.16

2587000

-6655000

302000

-706000

10000

15000

3498000

-6388000

6695000

152000

-6655000

-6676000

21000

6000

2000

2000000

152000

5500000

4108000

19000

649000

1.1688

0.0000

0.7942

0.0118

21.50

0.8912

0.0202

654869

9000 -2738000

39096

130046

212000

437000

P10Y

P5Y2M12D

637445

-3.36

752000

-2212000

4000

2216000

-2212000

-2216000

4000

1464000

128000

P10Y

0.0000

0.0146

22.70

1.1688

657609

52000

76000

-1.05

986000

-2476000

2476000

-2476000

1490000

43000

0.9199

0.0000

0.8387

0.0194

4.90

0.8793

0.0235

2351144

7000

36000

P10Y

P6Y2M30D

0001533040 us-gaap:MinimumMember 2017-07-01 2017-09-30 0001533040 us-gaap:MaximumMember 2017-07-01 2017-09-30 0001533040 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-07-01 2017-09-30 0001533040 us-gaap:ResearchAndDevelopmentExpenseMember 2017-07-01 2017-09-30 0001533040 2017-07-01 2017-09-30 0001533040 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-07-01 2016-09-30 0001533040 us-gaap:ResearchAndDevelopmentExpenseMember 2016-07-01 2016-09-30 0001533040 2016-07-01 2016-09-30 0001533040 us-gaap:CommonStockMember 2017-01-01 2017-03-31 0001533040 us-gaap:MinimumMember 2016-01-01 2016-09-30 0001533040 us-gaap:MaximumMember 2016-01-01 2016-09-30 0001533040 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-09-30 0001533040 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-09-30 0001533040 us-gaap:WarrantMember 2016-01-01 2016-09-30 0001533040 us-gaap:StockCompensationPlanMember 2016-01-01 2016-09-30 0001533040 2016-01-01 2016-09-30 0001533040 us-gaap:ScenarioPreviouslyReportedMember 2017-01-01 2017-09-30 0001533040 us-gaap:RestatementAdjustmentMember 2017-01-01 2017-09-30 0001533040 rxii:TwoThousandFifteenWarrantsMember 2017-01-01 2017-09-30 0001533040 rxii:TwoThousandSixteenWarrantsMember 2017-01-01 2017-09-30 0001533040 us-gaap:SeriesCPreferredStockMember 2017-01-01 2017-09-30 0001533040 us-gaap:SeriesBPreferredStockMember 2017-01-01 2017-09-30 0001533040 us-gaap:MinimumMember 2017-01-01 2017-09-30 0001533040 us-gaap:MaximumMember 2017-01-01 2017-09-30 0001533040 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-09-30 0001533040 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-09-30 0001533040 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001533040 us-gaap:StockCompensationPlanMember 2017-01-01 2017-09-30 0001533040 rxii:DerivativeAssetMember us-gaap:FairValueInputsLevel3Member 2017-01-01 2017-09-30 0001533040 2017-01-01 2017-09-30 0001533040 us-gaap:SubsequentEventMember 2018-01-03 2018-01-03 0001533040 rxii:MirimmuneStockPurchaseAgreementMember 2017-01-06 2017-01-06 0001533040 us-gaap:SeriesCPreferredStockMember 2017-01-06 2017-01-06 0001533040 2017-01-06 2017-01-06 0001533040 us-gaap:SeriesCPreferredStockMember 2017-01-05 2017-01-05 0001533040 rxii:LpcMember us-gaap:CommonStockMember 2017-08-08 2017-08-08 0001533040 us-gaap:SeriesCPreferredStockMember 2017-01-05 0001533040 us-gaap:SeriesCPreferredStockMember 2016-12-31 0001533040 us-gaap:SeriesBPreferredStockMember 2016-12-31 0001533040 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001533040 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001533040 us-gaap:FairValueInputsLevel3Member 2016-12-31 0001533040 2016-12-31 0001533040 2015-12-31 0001533040 rxii:TwoThousandFifteenWarrantsMember 2017-09-30 0001533040 rxii:TwoThousandSixteenWarrantsMember 2017-09-30 0001533040 us-gaap:SeriesCPreferredStockMember 2017-09-30 0001533040 us-gaap:SeriesBPreferredStockMember 2017-09-30 0001533040 us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0001533040 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0001533040 us-gaap:FairValueInputsLevel3Member 2017-09-30 0001533040 2017-09-30 0001533040 rxii:TwoThousandTwelveWarrantsMember 2017-06-30 0001533040 2016-09-30 0001533040 us-gaap:SeriesCPreferredStockMember 2017-06-09 0001533040 2018-03-15 0001533040 us-gaap:SeriesCPreferredStockMember us-gaap:SubsequentEventMember 2017-11-07 0001533040 us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2017-11-07 0001533040 rxii:LpcMember us-gaap:CommonStockMember 2017-08-08 0001533040 rxii:LpcMember us-gaap:MaximumMember us-gaap:CommonStockMember 2017-08-08 shares iso4217:USD shares iso4217:USD pure

EX-101.SCH 5 rxii-20170930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Nature of Operations link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Liquidity and Going Concern link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Recent Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - MirImmune Inc. Acquisition link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Stock-based Compensation link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Net Loss per Share link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Stock-based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Net Loss per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Nature of Operations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Significant Accounting Policies - Summary of Restatement of Consolidated Financial Statements - (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Reported Within Balance Sheet (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - MirImmune Inc. Acquisition - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Fair Value Measurements - Fair Value Measurements (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Fair Value Measurements - Schedule of Reconciliation of the Beginning and Ending Level 3 Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Stockholders' Equity - Summary of Warrants Outstanding (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used to Determine Fair Value of Option Grants (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Stock-based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Stock-based Compensation - Details of Stock-based Compensation Expense Recorded (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Net Loss per Share - Common Shares Excluded from the Calculation of Net Loss per Common Share Attributable to Common Stockholders (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 6 rxii-20170930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 rxii-20170930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 rxii-20170930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Receivable Type [Axis] Receivable Type [Axis] Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Additional number common stock to be issued upon milestone achievement percentage. Additional Number Common Stock To Be Issued Upon Milestone Achievement, Percentage Additional number of common stock to be issued upon milestone percentage Additional Paid in Capital Additional paid-in capital Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities Adjustments to reconcile net loss to net cash used in operating activities: Amendment Description Amendment Description Amendment Flag Amendment Flag Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Total amount of anti-dilutive securities excluded from computation of earnings per share Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] The entire disclosure for an asset acquisition completed during the period, including the nature and amount of such assets charged to expense during the period. Asset Acquisition Disclosure [Text Block] MirImmune Inc. Acquisition Assets Total assets Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] Current assets: Assets, Fair Value Disclosure Total Assets, Fair Value Disclosure [Abstract] Assets: Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Cash Acquired from Acquisition Cash acquired in MirImmune Inc. acquisition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash, cash equivalents and restricted cash within disposal group and discontinued operation. Cash And Cash Equivalents And Restricted Cash At Carrying Value Cash, cash equivalents and restricted cash at the end of period Cash, cash equivalents and restricted cash at the beginning of period Cash, cash equivalents and restricted cash shown in the statement of cash flows Amount of decrease in cash, cash equivalents and restricted cash. Cash, cash equivalents and restricted cash are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes. Cash And Cash Equivalents And Restricted Cash Period Increase Decrease Net decrease in cash, cash equivalents and restricted cash Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash, Cash Equivalents and Restricted Cash Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosure of non-cash investing and financing activities: Class of Stock [Domain] Class of Stock [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise prices Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Class of Warrant or Right, Outstanding Number of common stock, outstanding warrants Number of Shares Underlying Warrants Date the warrants or rights expire, in CCYY-MM-DD format. Class Of Warrant Or Rights Date From Which Warrants Or Rights Expire Expiration Class of Warrant or Right [Table] Class of Warrant or Right [Table] Commitments and Contingencies Commitments and contingencies Common Stock [Member] Common Stock [Member] Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Value, Issued Common stock, $0.0001 par value, 100,000,000 shares authorized; 2,369,733 and 1,300,318 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively Comprehensive Income, Policy [Policy Text Block] Comprehensive Loss Conversion of Stock, Amount Converted Conversions of convertible preferred stock into common stock Convertible Preferred Stock, Shares Issued upon Conversion Shares issued upon conversion Stock conversion ratio Current Fiscal Year End Date Current Fiscal Year End Date Deferred Income Tax Expense (Benefit) Deferred tax Deferred taxes Depreciation, Depletion and Amortization Depreciation and amortization Derivative Asset [Member] Derivative Asset [Member] Thera Warrant [Member] Derivative Asset Warrant in Thera Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-based Compensation Dividends, Preferred Stock Other dividends paid Document and entity information. Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Net loss per common share: Earnings Per Share, Basic and Diluted Basic and diluted Net loss per common share: basic and diluted Earnings Per Share, Policy [Policy Text Block] Net Loss per Share Earnings Per Share [Text Block] Net Loss per Share Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets Measured on Recurring Basis [Table Text Block] Fair Value Measurements Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of Reconciliation of the Beginning and Ending Level 3 Assets Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Measurements Fair Value, Inputs, Level 3 [Member] Unobservable Inputs (Level 3) [Member] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Measurements, Recurring [Member] Fair Value, Measurements, Recurring [Member] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease) Change in value of the warrant in Thera Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Balance, end of period Balance, beginning of period Fair Value of Assets Acquired Fair value of securities issued General and Administrative Expense General and administrative Holdback percentage of the aggregate closing consideration for purchase price of acquisition. Holdback Percentage Holdback of aggregate closing consideration, percentage Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Income Statement [Abstract] Consolidated Statement of Operations [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Income Tax Expense (Benefit) Income tax benefit Income tax expense (benefit) Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Interest Income (Expense), Nonoperating, Net Interest income, net Investment Company, Capital Share Transactions [Abstract] Investment Company, Capital Share Transactions [Abstract] Legal Entity [Axis] Legal Entity [Axis] Liabilities and Equity Total liabilities and stockholders' equity Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities: Lincoln Park Capital Fund, LLC. LPC [Member] Lincoln Park Capital Fund, LLC [Member] Maturities of Time Deposits, Description Liquid instrument maturity period Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] MirImmune stock purchase agreement. MirImmune Stock Purchase Agreement [Member] MirImmune Stock Purchase Agreement [Member] Nature of Operations [Text Block] Nature of Operations Nature of operations. Nature of Operations [Abstract] Nature Of Operations [Abstract] Nature of operations. Nature Of Operations [Line Items] Nature of Operations [Line Items] Nature of operations. Nature Of Operations [Table] Nature Of Operations [Table] Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net Income (Loss) Attributable to Parent Net loss Net loss New Accounting Pronouncements and Changes in Accounting Principles [Abstract] New Accounting Pronouncements and Changes in Accounting Principles [Abstract] New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Noncash or Part Noncash Acquisition, Payables Assumed Accounts payable assumed Nonoperating Income (Expense) Total other income Nonoperating Income (Expense) [Abstract] Other income (expense): Notes, Loans and Financing Receivable, Net, Noncurrent Notes receivable Notes Reduction Cancellation of notes receivable Operating Expenses Total operating expenses Total operating expenses Operating Expenses [Abstract] Operating expenses: Operating Income (Loss) Operating loss Operating loss Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Other Assets, Noncurrent Other assets Other Nonoperating Income (Expense) Other income (expense), net Payments to Acquire Property, Plant, and Equipment Cash paid for purchase of property and equipment Payments to Acquire Short-term Investments Purchase of short-term investments Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Convertible preferred stock, shares issued Preferred Stock, shares issued Preferred Stock, Shares Outstanding Preferred Stock, shares outstanding Preferred Stock, Value, Issued Preferred stock, par value Preferred Stock, Voting Rights Preferred stock voting rights Prepaid Expense, Current Prepaid expenses Reclassification, Policy [Policy Text Block] Restatement of Consolidated Financial Statements Proceeds from Issuance of Common Stock Proceeds from the issuance of common stock, net of offering costs Proceeds from Sale, Maturity and Collection of Investments Maturities of short-term investments Property, Plant and Equipment, Net Property and equipment, net Range [Axis] Range [Axis] Range [Domain] Range [Domain] Receivable [Domain] Receivable [Domain] Research and Development [Abstract] Research and Development [Abstract] Research and Development Asset Acquired Other than Through Business Combination, Written-off Acquired in-process research and development Research and Development Assets Acquired Other than Through Business Combination [Line Items] Research and Development Assets Acquired Other than Through Business Combination [Line Items] Research and Development Expense Research and development Research and Development Expense [Member] Research and Development [Member] Research and Development Expense, Policy [Policy Text Block] Research and Development Expenses Restatement Adjustment [Member] Adjustment [Member] Restricted Cash and Cash Equivalents Restricted cash Restricted Cash and Cash Equivalents, Current Restricted cash Retained Earnings (Accumulated Deficit) Accumulated deficit Revenues Net revenues Potential cash to be received on stock transaction.Value of common stock allocated to investors to buy shares of common stock of the Company. When stock is sold on this basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until the request for purchase is made by the issuer to the investor over the length of the agreement. Sale Of Stock Potential Consideration To Be Received On Transaction Potential consideration under purchase agreement Scenario, Previously Reported [Member] Previously Reported [Member] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Common Shares Excluded from the Calculation of Net Loss per Common Share Attributable to Common Stockholders Tabular disclosure of the components of cash, cash equivalents and restricted cash. Schedule of Cash Cash Equivalents and Restricted Cash [Table Text Block] Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Reported Within Balance Sheet Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Details of Stock-based Compensation Expense Recorded Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] Summary of Restatement of Consolidated Financial Statements Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table] Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of Stock Option Activity Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Assumptions Used to Determine Fair Value of Option Grants Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Summary of Warrants Outstanding Selling, General and Administrative Expenses [Member] General and Administrative [Member] Series B Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Series C Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Share-based Compensation Non-cash stock-based compensation Total stock-based compensation Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected lives (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected volatility, Maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility, Minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, Maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, Minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Weighted average expected volatility Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value, Exercisable EX-101.PRE 9 rxii-20170930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2017	Mar. 15, 2018
Document And Entity Information [Abstract]
Document Type	10-Q/A
Amendment Flag	true
Amendment Description	RXi Pharmaceuticals Corporation (“we,” “our,” “us” and the “Company”) is filing this Amendment No. 1 on Form 10-Q/A to amend and restate in their entirety the following items of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as originally filed with the Securities and Exchange Commission on November 8, 2017. (the “Original Form 10-Q”):•Part I - Item 1. Financial Statements (unaudited)•Part I - Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations•Part I - Item 4. Controls and Procedures• Part II - Item 6. Exhibits • Exhibit 31.1 - Certification of Chief Executive Officer• Exhibit 31.2 - Certification of Chief Financial Officer • Exhibits 101 - Extensible Business Reporting Language (XBRL) This amendment does not modify any disclosures contained in our original Form 10-Q, except for the foregoing Items and Exhibits, and all share and per share amounts for the periods presented to give effect to the 1-for-10 reverse stock split of the Company’s common stock, which was effected on January 8, 2018. This report on Form 10-Q/A is presented as of the filing date of the Original Form 10-Q and does not reflect events occurring after that date, or modify or update disclosures in any way other than as required to reflect the restatement described below. Accordingly, this Quarterly Report on Form 10-Q/A should be read in conjunction with the Original Form 10-Q, and the Company’s other filings with the Securities and Exchange Commission (“SEC”) subsequent to the filing of the Original Form 10-Q, including any amendments thereto.The purpose of this amendment is to restate our previously reported results for the quarter ended September 30, 2017 to include the accounting for the tax-related impact of the Company’s acquisition of MirImmune Inc. (“MirImmune”) on January 6, 2017. Our results did not include the contemplation of deferred taxes based on the different book basis and tax basis for the acquisition of MirImmune. The acquisition resulted in an increase of $1.6 million to acquired in-process research and development expense and a corresponding $1.6 million income tax benefit resulting from the reduction in the company's vluation allowance due to the deferred tax liability created as a result of the book and tax basis difference, which were not accounted for properly. The condensed consolidated financial statements for the quarter ended September 30, 2017 included in this Form 10-Q/A have been restated to include this adjustment to reflect the tax-related impact of the acquisition of MirImmune. This adjustment does not affect previously reported net loss or operating cash flows, although certain adjustments have been made in our condensed consolidated statement of cash flows to correspond to the income statement adjustment as described in Note 2 of the notes to our condensed consolidated financial statements included in this filing, and has no impact on the company's balance sheet. We have made necessary conforming changes in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” resulting from the correction of this error.
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Trading Symbol	RXII
Entity Registrant Name	RXi Pharmaceuticals Corp
Entity Central Index Key	0001533040
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		2,594,962

XML 11 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 5,416	$ 12,906
Restricted cash	50	50
Prepaid expenses	271	150
Total current assets	5,737	13,106
Property and equipment, net	269	114
Notes receivable		150
Other assets	27	27
Total assets	6,033	13,397
Current liabilities:
Accounts payable	702	917
Accrued expenses	1,901	1,625
Total current liabilities	2,603	2,542
Commitments and contingencies
Stockholders' equity:
Preferred stock, par value
Common stock, $0.0001 par value, 100,000,000 shares authorized; 2,369,733 and 1,300,318 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	0	0
Additional paid-in capital	79,979	73,429
Accumulated deficit	(76,549)	(66,099)
Total stockholders' equity	3,430	10,855
Total liabilities and stockholders' equity	6,033	13,397
Series B Convertible Preferred Stock [Member]
Stockholders' equity:
Preferred stock, par value		$ 3,525
Series C Convertible Preferred Stock [Member]
Stockholders' equity:
Preferred stock, par value	$ 0

XML 12 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	2,369,733	1,300,318
Common stock, shares outstanding	2,369,733	1,300,318
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	8,100	8,100
Preferred Stock, shares issued	0	5,737
Preferred Stock, shares outstanding	0	5,737
Series C Convertible Preferred Stock [Member]
Preferred stock, shares authorized	1,800,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0

XML 13 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Net revenues				$ 19
Operating expenses:
Research and development	$ 1,490	$ 1,464	$ 4,166	4,108
Acquired in-process research and development			4,696
General and administrative	986	752	3,209	2,587
Total operating expenses	2,476	2,216	12,071	6,695
Operating loss	(2,476)	(2,216)	(12,071)	(6,676)
Other income (expense):
Interest income, net		4		15
Other income (expense), net				6
Total other income		4		21
Loss before income taxes	(2,476)	(2,212)	(12,071)	(6,655)
Income tax benefit			1,621
Net loss	$ (2,476)	$ (2,212)	$ (10,450)	$ (6,655)
Net loss per common share:
Basic and diluted	$ (1.05)	$ (3.36)	$ (4.71)	$ (10.16)
Weighted average common shares: basic and diluted	2,351,144	657,609	2,216,775	654,869

XML 14 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net loss	$ (10,450)	$ (6,655)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	48	41
Non-cash stock-based compensation	276	649
Acquired in-process research and development	4,696
Deferred taxes	(1,621)
Value of non-marketable equity securities recognized as revenue		(9)
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(121)	(10)
Accounts payable	(417)	(706)
Accrued expenses	276	302
Net cash used in operating activities	(7,313)	(6,388)
Cash flows from investing activities:
Purchase of short-term investments		(2,000)
Maturities of short-term investments		5,500
Cash acquired in MirImmune Inc. acquisition	100
Cash paid for purchase of property and equipment	(203)	(2)
Net cash (used in) provided by investing activities	(103)	3,498
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of offering costs	(74)	152
Net cash (used in) provided by financing activities	(74)	152
Net decrease in cash, cash equivalents and restricted cash	(7,490)	(2,738)
Cash, cash equivalents and restricted cash at the beginning of period	12,956	5,167
Cash, cash equivalents and restricted cash at the end of period	5,466	$ 2,429
Supplemental disclosure of non-cash investing and financing activities:
Cancellation of notes receivable	150
Accounts payable assumed	5
Fair value of securities issued	2,824
Series B Convertible Preferred Stock [Member]
Supplemental disclosure of non-cash investing and financing activities:
Conversions of convertible preferred stock into common stock	3,525
Series C Convertible Preferred Stock [Member]
Supplemental disclosure of non-cash investing and financing activities:
Conversions of convertible preferred stock into common stock	$ 816

XML 15 R6.htm IDEA: XBRL DOCUMENT

Nature of Operations	9 Months Ended
Nature of Operations	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	1. Nature of Operations RXi Pharmaceuticals Corporation (“RXi,” “we,” “our” or the “Company”) is a clinical-stage company developing innovative therapeutics based on our proprietary self-delivering RNAi (sd-rxRNA^®) platform and Samcyprone™ which address significant unmet medical needs. We have a pipeline of discovery, preclinical and clinical product candidates in the areas of dermatology, ophthalmology and cell-based cancer immunotherapy. The Company’s clinical development programs include RXI-109, an sd-rxRNA for the treatment of dermal and ocular scarring, and Samcyprone™, a topical immunomodulator, for the treatment of warts. The Company’s pipeline, coupled with our extensive patent portfolio, provides for product development and business development opportunities across a broad spectrum of therapeutic areas. On January 3, 2018, the Board of Directors of the Company approved a 1-for-10 reverse stock split of the Company’s outstanding common stock, which was effected on January 8, 2018. All share and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split, including reclassifying an amount equal to the reduction in par value to additional paid-in capital.

XML 16 R7.htm IDEA: XBRL DOCUMENT

Liquidity and Going Concern	9 Months Ended
Liquidity and Going Concern	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	2. Liquidity and Going Concern The Company has limited cash resources, certain limitations under the purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”) and has expended substantial funds on the research and development of our product candidates and funding general operations. As a result, we have reported recurring losses from operations since inception and expect that we will continue to have negative cash flows from our operations for the foreseeable future. Historically, the Company’s primary source of financing has been the sale of its securities. Our ability to continue to fund our operations is dependent on the amount of cash on hand and our ability to raise additional capital through, but not limited to, equity or debt offerings or strategic opportunities. This is dependent on a number of factors, including the market demand or liquidity of our common stock. There can be no assurance that the Company will be successful in accomplishing these plans. As a result, we have concluded that there is substantial doubt regarding our ability to continue as a going concern for at least one year. If we fail to obtain additional funding when needed, we would be forced to scale back or terminate our operations or to seek to merge with or to be acquired by another company. These financial statements do not include any adjustments to, or classification of, recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

XML 17 R8.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Significant Accounting Policies

3. Significant Accounting Policies

Restatement of Consolidated Financial Statements


	Nine Months Ended September 30, 2017
	Previously Reported			Adjustment			Restated
	($ in thousands, except per share data)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS:
Operating Expenses:
Research and development	$	4,166		$	—		$	4,166
Acquired in-process research and development		3,075			1,621			4,696
General and administrative		3,209			—			3,209

Total operating expenses		10,450			1,621			12,071

Operating loss		(10,450	)		(1,621	)		(12,071	)

Loss before income taxes		(10,450	)		(1,621	)		(12,071	)
Income tax benefit		—			1,621			1,621

Net loss	$	(10,450	)	$	—		$	(10,450	)

Net loss per common share: basic and diluted	$	(4.71	)	$	—		$	(4.71	)
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS:
Cash flows from operating activities:
Net loss	$	(10,450	)	$	—		$	(10,450	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization		48			—			48
Non-cash stock-based compensation		276			—			276
Acquired in-process research and development		3,075			1,621			4,696
Deferred tax		—			(1,621	)		(1,621	)
Changes in operating assets and liabilities:
Prepaid expenses and other assets		(121	)		—			(121	)
Accounts payable		(417	)		—			(417	)
Accrued expenses		276			—			276

Net cash used in operating expenses	$	(7,313	)	$	—		$	(7,313	)

Basis of Presentation

Uses of Estimates in Preparation of Financial Statements

Cash, Cash Equivalents and Restricted Cash

Restricted cash consists of certificates of deposit held by financial institutions as collateral for the Company’s corporate credit cards.


	September 30,		December 31,
	2017		2016
Cash and cash equivalents		5,416		12,906
Restricted cash		50		50

Cash, cash equivalents and restricted cash shown in the statement of cash flows		5,466		12,956

Research and Development Expenses

Stock-based Compensation

Comprehensive Loss

The Company’s comprehensive loss is equal to its net loss for all periods presented.

Net Loss per Share

XML 18 R9.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements	9 Months Ended
Recent Accounting Pronouncements	Sep. 30, 2017
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	4. Recent Accounting Pronouncements In August 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-15, “Statement of Cash Flows (Topic 230) — Classification of Certain Cash Receipts and Cash Payments,” which clarifies how certain cash receipts and payments are presented and classified in the statement of cash flows. This standard will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted. The amendments in ASU 2016-15 should be applied using a retrospective transition method to each period presented. The Company adopted ASU 2016-15 in the first quarter of 2017 and the implementation of this standard had no impact on the Company’s financial statements. In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230) — Restricted Cash,” which requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash and restricted cash equivalents. With this standard, amounts generally described as restricted cash or restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning of period and end of period total amounts shown on the statement of cash flows. This standard will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted. The Company adopted ASU 2016-18 in the first quarter of 2017, and the guidance has been retrospectively applied to all periods presented. The total of cash, cash equivalents and restricted cash is described in Note 3. The adoption of the guidance did not have an impact on the Company’s balance sheet or statement of operations. In January 2017, the FASB issued ASU 2017-01, “Business Combinations (Topic 805) — Clarifying the Definition of a Business,” which provides a screen to determine when an integrated set of assets and activities are not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. This standard will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. The Company adopted ASU 2017-01 effective January 1, 2017. The implementation of this standard did not have an impact on the Company’s financial statements as the acquisition of MirImmune Inc., (“MirImmune”), the Company’s transaction that this ASU would have affected, did not meet the definition of a business under either the prior guidance or the new guidance. In May 2017, the FASB issued ASU 2017-09, “Compensation — Stock Compensation (Topic 718) — Scope of Modification Accounting,” which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. This standard will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted. The Company adopted ASU 2017-09 in the second quarter of 2017, and the implementation of this standard had no impact on the Company’s financial statements.

XML 19 R10.htm IDEA: XBRL DOCUMENT

MirImmune Inc. Acquisition	9 Months Ended
MirImmune Inc. Acquisition	Sep. 30, 2017
Research and Development [Abstract]
MirImmune Inc. Acquisition	5. MirImmune Inc. Acquisition On January 6, 2017, the Company entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) and completed its acquisition of MirImmune. Subject to the terms of the Stock Purchase Agreement, RXi Merger Sub, LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company (“RXi Merger Sub”), was merged with and into MirImmune, with RXi Merger Sub continuing as the surviving entity and changing its name to “MirImmune, LLC”. As a result of the merger, MirImmune, LLC remains and operates as a wholly-owned subsidiary of the Company. Pursuant to the Stock Purchase Agreement, the Company acquired all of the issued and outstanding shares of capital stock of MirImmune for an aggregate of 275,036 shares of common stock of the Company and an aggregate of 1,118,224 shares of Series C Convertible Preferred Stock of the Company (the “Series C Convertible Preferred Stock”). The shares of common stock and Series C Convertible Preferred Stock were subject to a holdback of 3% of the aggregate closing consideration for any purchase price adjustments. The shares subject to the holdback, adjusted for post-closing items, were released and issued on April 12, 2017. Upon the closing of the acquisition, the notes receivable outstanding on the Company’s balance sheet as of December 31, 2016 were cancelled. The Company assessed the acquisition of MirImmune under FASB ASC Topic 805, “Business Combinations” (“ASC 805”). Under ASC 805, the Company determined that the acquired assets did not constitute a business and that the transaction would be accounted for as an asset acquisition. The assets and development programs acquired from MirImmune are at an early stage of development and will require a significant investment of time and capital if we are to be successful in developing them. There is no assurance that we will be successful in developing such assets, and a failure to successfully develop such assets could diminish our prospects. Under ASC 805, the assets acquired are considered to have no alternative future uses, as determining the future economic benefit of the acquired assets at the date of acquisition is highly uncertain. The fair value of the assets was determined using the quoted market price of the Company’s common stock on January 6, 2017, the date of the acquisition, and fully expensed as in-process research and development. Additionally, the Company assessed the MirImmune acquisition under ASC Topic 740, “Income Taxes” (“ASC 740”). The acquisition resulted in an income tax benefit of $1,621,000 and a corresponding increase to acquired in-process research and development expense resulting from the reduction in the Company’s valuation allowance due to the deferred tax liability created as a result of the book and tax basis difference. During the nine months ended September 30, 2017, the Company recorded $4,696,000 in in-process research and development expense related to the fair value of consideration given, which includes transaction costs, liabilities assumed and cancellation of notes receivable, and the deferred tax impact of the MirImmune acquisition. The Company was restricted from converting any of the Series C Convertible Preferred Stock into common stock to the extent that such conversion was not approved by the Company’s stockholders in accordance with the stockholder approval requirements of NASDAQ Marketplace Rule 5635. On June 9, 2017, with the approval of the Company’s stockholders in accordance with the NASDAQ stockholder approval requirements, every ten shares of the Series C Convertible Preferred Stock outstanding were automatically converted into one share of common stock, such that there were no shares of Series C Convertible Preferred Stock issued or outstanding at September 30, 2017. On November 7, 2017, the Company filed a Certificate Eliminating the Series C Convertible Preferred Stock from the Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware. Please refer to Note 10 for further discussion of the filing. Under the terms of the Stock Purchase Agreement, if certain development or commercial milestones are achieved within two years, the Company will be required to either (i) issue a number of shares of common stock (the “Milestone Shares”) equal to the sum of 251,909 shares of common stock, plus an additional number of shares of common stock equal to 13% of the common stock issued upon exercise of any warrants issued under the Company’s underwritten public offering in December 2016, but only to the extent that such warrants have been exercised prior to the milestone being achieved or (ii) pay the equivalent value of the Milestone Shares in cash. The Company received shareholder approval in accordance with Rule 5635 of the NASDAQ Marketplace Rules at its 2017 Annual Meeting of Stockholders to issue any shares in satisfaction of the achievement of the milestones. The Company assessed the Milestone Shares under FASB ASC Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”). The Company determined that liability accounting would be required for the Milestone Shares under ASC 480. The Company will record a liability related to the Milestone Shares if and when the milestones are achieved and the consideration becomes payable. At that time, the Company will record the cost of the Milestone Shares as in-process research and development expense. No milestones have been met as of September 30, 2017.

XML 20 R11.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

9 Months Ended

Sep. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurements

6. Fair Value Measurements

Level 1 — quoted prices in active markets for identical assets or liabilities.

Level 2 — other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

Level 3 — significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

Financial assets measured at fair value on a recurring basis are summarized as follows, in thousands:


Description	At September 30, 2017		Quoted Prices in Active Markets (Level 1)		Other Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Warrant in Thera	$	5	$	—	$	—	$	5

Total	$	5	$	—	$	—	$	5


Description	At December 31, 2016		Quoted Prices in Active Markets (Level 1)		Other Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Warrant in Thera	$	5	$	—	$	—	$	5

Total	$	5	$	—	$	—	$	5

A reconciliation of the beginning and ending Level 3 assets for the nine months ended September 30, 2017 is as follows (in thousands):


	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, beginning of period	$	5
Change in value of the warrant in Thera		—

Balance, end of period	$	5

Fair Value of Financial Instruments

The carrying amounts reported in the balance sheet for cash equivalents, restricted cash and accounts payable approximate their fair values due to their short-term nature.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 21 R12.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2017

Equity [Abstract]

Stockholders' Equity

7. Stockholders’ Equity

Lincoln Park Capital Fund, LLC — On August 8, 2017, the Company entered into a purchase agreement (the “2017 Purchase Agreement”) and a registration rights agreement with LPC, pursuant to which the Company has the right to sell to LPC up to $15,000,000 in shares of the Company’s common stock, subject to certain limitations and conditions set forth in the 2017 Purchase Agreement. As a commitment fee for entering into the 2017 Purchase Agreement, the Company issued to LPC 45,000 shares of Company common stock (the “Commitment Shares”). The Commitment Shares had a value per share of $5.80 and were recorded as a cost of capital. The Company intends to use the net proceeds from the 2017 Purchase Agreement for working capital and general corporate purposes. There have been no purchases under the 2017 Purchase Agreement as of September 30, 2017.

Warrants — The following table summarizes the Company’s outstanding warrants at September 30, 2017:


Exercise prices	Number of Shares Underlying Warrants		Expiration
$52.00		130,007		June 2, 2020
$9.00		1,277,993		December 21, 2021

Total warrants outstanding		1,408,000

During the second quarter of 2017, outstanding warrants for the purchase of 46 shares of the Company’s common stock with an exercise price of $390.00 expired.

No warrants were exercised during the nine months ended September 30, 2017 or 2016.

XML 22 R13.htm IDEA: XBRL DOCUMENT

Stock-based Compensation

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-based Compensation

8. Stock-based Compensation


	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2017			2016			2017			2016
Risk-free interest rate		1.94 – 2.35	%		1.46	%		1.73 – 2.49	%		1.18 – 2.02	%
Expected volatility		83.87 – 91.99	%		116.88	%		82.99 – 123.01	%		79.42 – 116.88	%
Weighted average expected volatility		87.93	%		116.88	%		84.65	%		89.12	%
Expected lives (in years)		6.25 – 10.00			10.00			5.20 – 10.00			5.20 – 10.00
Expected dividend yield		0.00	%		0.00	%		0.00	%		0.00	%

The following table summarizes the activity of Company’s stock option plan for the nine months ended September 30, 2017:


	Total Number of Shares			Weighted-Average Exercise Price Per Share		Aggregate Intrinsic Value
Balance at December 31, 2016		37,444		$	272.90
Granted		33,038			6.90
Exercised		—			—
Cancelled		(17,382	)		44.80

Balance at September 30, 2017		53,100		$	182.00	$	—

Exercisable at September 30, 2017		35,495		$	262.10	$	—

The Company recorded stock-based compensation expense for the three and nine months ended September 30, 2017 and 2016 as follows, in thousands:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Research and development	$	7	$	52	$	80	$	212
General and administrative		36		76		196		437

Total stock-based compensation	$	43	$	128	$	276	$	649

XML 23 R14.htm IDEA: XBRL DOCUMENT

Net Loss per Share

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Net Loss per Share

9. Net Loss per Share

The following table sets forth the potential common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:


	September 30,
	2017		2016
Options to purchase common stock		53,100		39,096
Warrants to purchase common stock		1,408,000		130,046

Total		1,461,100		169,142

XML 24 R15.htm IDEA: XBRL DOCUMENT

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events On November 7, 2017, the Company filed a Certificate Eliminating the Series B Convertible Preferred Stock from the Certificate of Incorporation of the Company and a Certificate Eliminating the Series C Convertible Preferred Stock from the Certificate of Incorporation of the Company (together, the “Certificates of Elimination”) with the Secretary of State of the State of Delaware, in order to eliminate from the Certificate of Incorporation all matters set forth in the Certificate of Incorporation, including the related certificates of designation, relating to the previously issued Series B Convertible Preferred Stock and Series C Convertible Preferred Stock. As a result, the 8,100 shares of unissued Series B Convertible Preferred Stock and 1,800,000 shares of unissued Series C Convertible Preferred Stock were returned to the status of authorized but unissued shares of preferred stock of the Company, without designation as to series or preferences or rights. The foregoing summary of the Certificates of Elimination is qualified in its entirety by reference to the full text of the Certificates of Elimination, which are attached hereto as Exhibits 3.1 and 3.2 to this Quarterly Report on Form 10-Q and incorporated herein by reference.

XML 25 R16.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Restatement of Consolidated Financial Statements

Restatement of Consolidated Financial Statements


	Nine Months Ended September 30, 2017
	Previously Reported			Adjustment			Restated
	($ in thousands, except per share data)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS:
Operating Expenses:
Research and development	$	4,166		$	—		$	4,166
Acquired in-process research and development		3,075			1,621			4,696
General and administrative		3,209			—			3,209

Total operating expenses		10,450			1,621			12,071

Operating loss		(10,450	)		(1,621	)		(12,071	)

Loss before income taxes		(10,450	)		(1,621	)		(12,071	)
Income tax benefit		—			1,621			1,621

Net loss	$	(10,450	)	$	—		$	(10,450	)

Net loss per common share: basic and diluted	$	(4.71	)	$	—		$	(4.71	)
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS:
Cash flows from operating activities:
Net loss	$	(10,450	)	$	—		$	(10,450	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization		48			—			48
Non-cash stock-based compensation		276			—			276
Acquired in-process research and development		3,075			1,621			4,696
Deferred tax		—			(1,621	)		(1,621	)
Changes in operating assets and liabilities:
Prepaid expenses and other assets		(121	)		—			(121	)
Accounts payable		(417	)		—			(417	)
Accrued expenses		276			—			276

Net cash used in operating expenses	$	(7,313	)	$	—		$	(7,313	)

Basis of Presentation

Basis of Presentation

Uses of Estimates in Preparation of Financial Statements

Uses of Estimates in Preparation of Financial Statements

Cash, Cash Equivalents and Restricted Cash

Cash, Cash Equivalents and Restricted Cash

Restricted cash consists of certificates of deposit held by financial institutions as collateral for the Company’s corporate credit cards.


	September 30,		December 31,
	2017		2016
Cash and cash equivalents		5,416		12,906
Restricted cash		50		50

Cash, cash equivalents and restricted cash shown in the statement of cash flows		5,466		12,956

Research and Development Expenses

Research and Development Expenses

Stock-based Compensation

Stock-based Compensation

Comprehensive Loss

Comprehensive Loss

The Company’s comprehensive loss is equal to its net loss for all periods presented.

Net Loss per Share

Net Loss per Share

XML 26 R17.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Summary of Restatement of Consolidated Financial Statements

The following table summarizes the effects of our restatement on the nine months ended September 30, 2017 resulting from the correction of this error.


	Nine Months Ended September 30, 2017
	Previously Reported			Adjustment			Restated
	($ in thousands, except per share data)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS:
Operating Expenses:
Research and development	$	4,166		$	—		$	4,166
Acquired in-process research and development		3,075			1,621			4,696
General and administrative		3,209			—			3,209

Total operating expenses		10,450			1,621			12,071

Operating loss		(10,450	)		(1,621	)		(12,071	)

Loss before income taxes		(10,450	)		(1,621	)		(12,071	)
Income tax benefit		—			1,621			1,621

Net loss	$	(10,450	)	$	—		$	(10,450	)

Net loss per common share: basic and diluted	$	(4.71	)	$	—		$	(4.71	)
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS:
Cash flows from operating activities:
Net loss	$	(10,450	)	$	—		$	(10,450	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization		48			—			48
Non-cash stock-based compensation		276			—			276
Acquired in-process research and development		3,075			1,621			4,696
Deferred tax		—			(1,621	)		(1,621	)
Changes in operating assets and liabilities:
Prepaid expenses and other assets		(121	)		—			(121	)
Accounts payable		(417	)		—			(417	)
Accrued expenses		276			—			276

Net cash used in operating expenses	$	(7,313	)	$	—		$	(7,313	)

Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Reported Within Balance Sheet


	September 30,		December 31,
	2017		2016
Cash and cash equivalents		5,416		12,906
Restricted cash		50		50

Cash, cash equivalents and restricted cash shown in the statement of cash flows		5,466		12,956

XML 27 R18.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurements

Financial assets measured at fair value on a recurring basis are summarized as follows, in thousands:


Description	At September 30, 2017		Quoted Prices in Active Markets (Level 1)		Other Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Warrant in Thera	$	5	$	—	$	—	$	5

Total	$	5	$	—	$	—	$	5


Description	At December 31, 2016		Quoted Prices in Active Markets (Level 1)		Other Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Warrant in Thera	$	5	$	—	$	—	$	5

Total	$	5	$	—	$	—	$	5

Schedule of Reconciliation of the Beginning and Ending Level 3 Assets

A reconciliation of the beginning and ending Level 3 assets for the nine months ended September 30, 2017 is as follows (in thousands):


	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, beginning of period	$	5
Change in value of the warrant in Thera		—

Balance, end of period	$	5

XML 28 R19.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2017

Equity [Abstract]

Summary of Warrants Outstanding

The following table summarizes the Company’s outstanding warrants at September 30, 2017:


Exercise prices	Number of Shares Underlying Warrants		Expiration
$52.00		130,007		June 2, 2020
$9.00		1,277,993		December 21, 2021

Total warrants outstanding		1,408,000

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 29 R20.htm IDEA: XBRL DOCUMENT

Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Assumptions Used to Determine Fair Value of Option Grants


	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2017			2016			2017			2016
Risk-free interest rate		1.94 – 2.35	%		1.46	%		1.73 – 2.49	%		1.18 – 2.02	%
Expected volatility		83.87 – 91.99	%		116.88	%		82.99 – 123.01	%		79.42 – 116.88	%
Weighted average expected volatility		87.93	%		116.88	%		84.65	%		89.12	%
Expected lives (in years)		6.25 – 10.00			10.00			5.20 – 10.00			5.20 – 10.00
Expected dividend yield		0.00	%		0.00	%		0.00	%		0.00	%

Summary of Stock Option Activity

The following table summarizes the activity of Company’s stock option plan for the nine months ended September 30, 2017:


	Total Number of Shares			Weighted-Average Exercise Price Per Share		Aggregate Intrinsic Value
Balance at December 31, 2016		37,444		$	272.90
Granted		33,038			6.90
Exercised		—			—
Cancelled		(17,382	)		44.80

Balance at September 30, 2017		53,100		$	182.00	$	—

Exercisable at September 30, 2017		35,495		$	262.10	$	—

Details of Stock-based Compensation Expense Recorded

The Company recorded stock-based compensation expense for the three and nine months ended September 30, 2017 and 2016 as follows, in thousands:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Research and development	$	7	$	52	$	80	$	212
General and administrative		36		76		196		437

Total stock-based compensation	$	43	$	128	$	276	$	649

XML 30 R21.htm IDEA: XBRL DOCUMENT

Net Loss per Share (Tables)

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Common Shares Excluded from the Calculation of Net Loss per Common Share Attributable to Common Stockholders

The following table sets forth the potential common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:


	September 30,
	2017		2016
Options to purchase common stock		53,100		39,096
Warrants to purchase common stock		1,408,000		130,046

Total		1,461,100		169,142

XML 31 R22.htm IDEA: XBRL DOCUMENT

Nature of Operations - Additional Information (Detail) - Subsequent Events [Member]	Jan. 03, 2018
Nature of Operations [Line Items]
Stock split description	Company approved a 1-for-10 reverse stock split of the Company's outstanding common stock, which was effected on January 8, 2018.
Reverse stock split ratio	0.001

XML 32 R23.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Summary of Restatement of Consolidated Financial Statements - (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Operating expenses:
Research and development	$ 1,490	$ 1,464	$ 4,166	$ 4,108
Acquired in-process research and development			4,696
General and administrative	986	752	3,209	2,587
Total operating expenses	2,476	2,216	12,071	6,695
Operating loss	(2,476)	(2,216)	(12,071)	(6,676)
Loss before income taxes	(2,476)	(2,212)	(12,071)	(6,655)
Income tax benefit			1,621
Net loss	$ (2,476)	$ (2,212)	$ (10,450)	$ (6,655)
Net loss per common share: basic and diluted	$ (1.05)	$ (3.36)	$ (4.71)	$ (10.16)
Cash flows from operating activities:
Net loss	$ (2,476)	$ (2,212)	$ (10,450)	$ (6,655)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization			48	41
Non-cash stock-based compensation	$ 43	$ 128	276	649
Acquired in-process research and development			4,696
Deferred tax			(1,621)
Changes in operating assets and liabilities:
Prepaid expenses and other assets			(121)	(10)
Accounts payable			(417)	(706)
Accrued expenses			276	302
Net cash used in operating activities			(7,313)	$ (6,388)
Previously Reported [Member]
Operating expenses:
Research and development			4,166
Acquired in-process research and development			3,075
General and administrative			3,209
Total operating expenses			10,450
Operating loss			(10,450)
Loss before income taxes			(10,450)
Net loss			$ (10,450)
Net loss per common share: basic and diluted			$ (4.71)
Cash flows from operating activities:
Net loss			$ (10,450)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization			48
Non-cash stock-based compensation			276
Acquired in-process research and development			3,075
Changes in operating assets and liabilities:
Prepaid expenses and other assets			(121)
Accounts payable			(417)
Accrued expenses			276
Net cash used in operating activities			(7,313)
Adjustment [Member]
Operating expenses:
Acquired in-process research and development			1,621
Total operating expenses			1,621
Operating loss			(1,621)
Loss before income taxes			(1,621)
Income tax benefit			1,621
Adjustments to reconcile net loss to net cash used in operating activities
Acquired in-process research and development			1,621
Deferred tax			$ (1,621)

XML 33 R24.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Liquid instrument maturity period	Three months or less

XML 34 R25.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Reported Within Balance Sheet (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Cash and cash equivalents	$ 5,416	$ 12,906
Restricted cash	50	50
Cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 5,466	$ 12,956	$ 2,429	$ 5,167

XML 35 R26.htm IDEA: XBRL DOCUMENT

MirImmune Inc. Acquisition - Additional Information (Detail) - USD ($) $ in Thousands		9 Months Ended
	Jan. 06, 2017	Sep. 30, 2017	Jun. 09, 2017	Dec. 31, 2016
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
Number of shares acquired	275,036	275,036
Holdback of aggregate closing consideration, percentage	3.00%
Income tax expense (benefit)		$ 1,621
Acquired in-process research and development		$ 4,696
MirImmune Stock Purchase Agreement [Member]
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
Shares of common stock to be issued upon milestone	251,909
Additional number of common stock to be issued upon milestone percentage	13.00%
Series C Convertible Preferred Stock [Member]
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
Number of shares acquired	1,118,224	1,118,224
Stock conversion ratio		1	1
Preferred Stock, shares issued		0		0
Preferred Stock, shares outstanding		0		0

XML 36 R27.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Fair Value Measurements (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Assets:
Warrant in Thera	$ 5	$ 5
Total	5	5
Unobservable Inputs (Level 3) [Member]
Assets:
Warrant in Thera	5	5
Total	$ 5	$ 5

XML 37 R28.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Reconciliation of the Beginning and Ending Level 3 Assets (Detail) - Unobservable Inputs (Level 3) [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2017 USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance, beginning of period	$ 5
Balance, end of period	5
Thera Warrant [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in value of the warrant in Thera	$ 0

XML 38 R29.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Additional Information (Detail) - USD ($)				3 Months Ended	9 Months Ended
	Aug. 08, 2017	Jan. 06, 2017	Jan. 05, 2017	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2017	Jun. 09, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Number of common stock issued upon conversion of convertible instrument					0	0
Preferred stock, shares authorized					10,000,000				10,000,000
Number of shares acquired		275,036			275,036
Number of common stock, outstanding warrants					1,408,000
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, shares outstanding					0				5,737
Convertible preferred stock, shares issued					0				5,737
Preferred stock, shares authorized					8,100				8,100
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, shares outstanding					0				0
Convertible preferred stock, shares issued					0				0
Preferred stock, shares authorized			1,800,000		1,800,000
Preferred stock voting rights					No voting rights, with certain exceptions
Other dividends paid			$ 0
Number of shares acquired		1,118,224			1,118,224
Shares issued upon conversion					1			1
Common Stock [Member]
Class of Stock [Line Items]
Number of common stock issued upon conversion of convertible instrument				637,445
Common Stock [Member] \| Lincoln Park Capital Fund, LLC [Member]
Class of Stock [Line Items]
Number of common stock issued as a commitment fee	45,000
Cost of capital, value per share	$ 5.80
Common Stock [Member] \| Lincoln Park Capital Fund, LLC [Member] \| Maximum [Member]
Class of Stock [Line Items]
Potential consideration under purchase agreement	15,000,000
Warrants With Exercise Price $390.00 [Member]
Class of Stock [Line Items]
Exercise prices							$ 390.00
Number of common stock, outstanding warrants							46

XML 39 R30.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Warrants Outstanding (Detail)	9 Months Ended
	Sep. 30, 2017 $ / shares shares
Class of Warrant or Right [Line Items]
Number of Shares Underlying Warrants	1,408,000
Warrants With Exercise Price $52.00 [Member]
Class of Warrant or Right [Line Items]
Exercise prices \| $ / shares	$ 52.00
Number of Shares Underlying Warrants	130,007
Expiration	Jun. 02, 2020
2016 Warrants With Exercise Price $9.00 [Member]
Class of Warrant or Right [Line Items]
Exercise prices \| $ / shares	$ 9.00
Number of Shares Underlying Warrants	1,277,993
Expiration	Dec. 21, 2021

XML 40 R31.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Schedule of Assumptions Used to Determine Fair Value of Option Grants (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate		1.46%
Risk-free interest rate, Minimum	1.94%		1.73%	1.18%
Risk-free interest rate, Maximum	2.35%		2.49%	2.02%
Expected volatility		116.88%
Expected volatility, Minimum	83.87%		82.99%	79.42%
Expected volatility, Maximum	91.99%		123.01%	116.88%
Weighted average expected volatility	87.93%	116.88%	84.65%	89.12%
Expected lives (in years)		10 years
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected lives (in years)	6 years 2 months 30 days		5 years 2 months 12 days	5 years 2 months 12 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected lives (in years)	10 years		10 years	10 years

XML 41 R32.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted average grant date fair value per share of options granted	$ 4.90	$ 22.70	$ 4.90	$ 21.50
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Stock-based compensation expense			$ 22,000

XML 42 R33.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Summary of Stock Option Activity (Detail)	9 Months Ended
	Sep. 30, 2017 USD ($) $ / shares shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Total Number of Shares, Beginning Balance \| shares	37,444
Total Number of Shares, Granted \| shares	33,038
Total Number of Shares, Exercised \| shares	0
Total Number of Shares, Cancelled \| shares	(17,382)
Total Number of Shares, Ending Balance \| shares	53,100
Total Number of Shares, Exercisable \| shares	35,495
Weighted-Average Exercise Price Per Share, Beginning Balance \| $ / shares	$ 272.90
Weighted-Average Exercise Price Per Share, Granted \| $ / shares	6.90
Weighted-Average Exercise Price Per Share, Exercised \| $ / shares	0
Weighted-Average Exercise Price Per Share, Cancelled \| $ / shares	44.80
Weighted-Average Exercise Price Per Share, Ending Balance \| $ / shares	182.00
Weighted-Average Exercise Price Per Share, Exercisable \| $ / shares	$ 262.10
Aggregate Intrinsic Value, Ending Balance \| $	$ 0
Aggregate Intrinsic Value, Exercisable \| $	$ 0

XML 43 R34.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Details of Stock-based Compensation Expense Recorded (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 43	$ 128	$ 276	$ 649
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	7	52	80	212
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 36	$ 76	$ 196	$ 437

XML 44 R35.htm IDEA: XBRL DOCUMENT

Net Loss per Share - Common Shares Excluded from the Calculation of Net Loss per Common Share Attributable to Common Stockholders (Detail) - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total amount of anti-dilutive securities excluded from computation of earnings per share	1,461,100	169,142
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total amount of anti-dilutive securities excluded from computation of earnings per share	53,100	39,096
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total amount of anti-dilutive securities excluded from computation of earnings per share	1,408,000	130,046

XML 45 R36.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Detail) - shares	Nov. 07, 2017	Sep. 30, 2017	Jan. 05, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Preferred stock, shares authorized		10,000,000		10,000,000
Series C Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock, shares authorized		1,800,000	1,800,000
Series B Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock, shares authorized		8,100		8,100
Subsequent Events [Member] \| Series C Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock, shares authorized	1,800,000
Subsequent Events [Member] \| Series B Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock, shares authorized	8,100

EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 47 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 48 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 60 146 1 false 20 0 false 4 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.rxipharma.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Consolidated Balance Sheets Sheet http://www.rxipharma.com/taxonomy/role/StatementOfFinancialPositionClassified Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.rxipharma.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Consolidated Statements of Operations Sheet http://www.rxipharma.com/taxonomy/role/StatementOfIncomeAlternative Consolidated Statements of Operations Statements 4 false false R5.htm 106 - Statement - Consolidated Statements of Cash Flows Sheet http://www.rxipharma.com/taxonomy/role/StatementOfCashFlowsIndirect Consolidated Statements of Cash Flows Statements 5 false false R6.htm 107 - Disclosure - Nature of Operations Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations Nature of Operations Notes 6 false false R7.htm 108 - Disclosure - Liquidity and Going Concern Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsSubstantialDoubtAboutGoingConcernTextBlock Liquidity and Going Concern Notes 7 false false R8.htm 109 - Disclosure - Significant Accounting Policies Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Significant Accounting Policies Notes 8 false false R9.htm 110 - Disclosure - Recent Accounting Pronouncements Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock Recent Accounting Pronouncements Notes 9 false false R10.htm 111 - Disclosure - MirImmune Inc. Acquisition Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsAssetAcquisitionDisclosureTextBlock MirImmune Inc. Acquisition Notes 10 false false R11.htm 112 - Disclosure - Fair Value Measurements Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value Measurements Notes 11 false false R12.htm 113 - Disclosure - Stockholders' Equity Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Stockholders' Equity Notes 12 false false R13.htm 114 - Disclosure - Stock-based Compensation Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-based Compensation Notes 13 false false R14.htm 115 - Disclosure - Net Loss per Share Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Net Loss per Share Notes 14 false false R15.htm 116 - Disclosure - Subsequent Events Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Events Notes 15 false false R16.htm 117 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Significant Accounting Policies (Policies) Policies http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 16 false false R17.htm 118 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables Significant Accounting Policies (Tables) Tables http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 17 false false R18.htm 119 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value Measurements (Tables) Tables http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock 18 false false R19.htm 120 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables Stockholders' Equity (Tables) Tables http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock 19 false false R20.htm 121 - Disclosure - Stock-based Compensation (Tables) Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock-based Compensation (Tables) Tables http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock 20 false false R21.htm 122 - Disclosure - Net Loss per Share (Tables) Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Net Loss per Share (Tables) Tables http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock 21 false false R22.htm 123 - Disclosure - Nature of Operations - Additional Information (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformation Nature of Operations - Additional Information (Detail) Details 22 false false R23.htm 124 - Disclosure - Significant Accounting Policies - Summary of Restatement of Consolidated Financial Statements - (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfRestatementOfConsolidatedFinancialStatements Significant Accounting Policies - Summary of Restatement of Consolidated Financial Statements - (Detail) Details 23 false false R24.htm 125 - Disclosure - Significant Accounting Policies - Additional Information (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation Significant Accounting Policies - Additional Information (Detail) Details 24 false false R25.htm 126 - Disclosure - Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Reported Within Balance Sheet (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheet Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Reported Within Balance Sheet (Detail) Details 25 false false R26.htm 127 - Disclosure - MirImmune Inc. Acquisition - Additional Information (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureMirImmuneIncAcquisitionAdditionalInformation MirImmune Inc. Acquisition - Additional Information (Detail) Details 26 false false R27.htm 128 - Disclosure - Fair Value Measurements - Fair Value Measurements (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurements Fair Value Measurements - Fair Value Measurements (Detail) Details 27 false false R28.htm 129 - Disclosure - Fair Value Measurements - Schedule of Reconciliation of the Beginning and Ending Level 3 Assets (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfReconciliationOfTheBeginningAndEndingLevel3Assets Fair Value Measurements - Schedule of Reconciliation of the Beginning and Ending Level 3 Assets (Detail) Details 28 false false R29.htm 130 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation Stockholders' Equity - Additional Information (Detail) Details 29 false false R30.htm 131 - Disclosure - Stockholders' Equity - Summary of Warrants Outstanding (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstanding Stockholders' Equity - Summary of Warrants Outstanding (Detail) Details 30 false false R31.htm 132 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used to Determine Fair Value of Option Grants (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfOptionGrants Stock-based Compensation - Schedule of Assumptions Used to Determine Fair Value of Option Grants (Detail) Details 31 false false R32.htm 133 - Disclosure - Stock-based Compensation - Additional Information (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformation Stock-based Compensation - Additional Information (Detail) Details 32 false false R33.htm 134 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivity Stock-based Compensation - Summary of Stock Option Activity (Detail) Details 33 false false R34.htm 135 - Disclosure - Stock-based Compensation - Details of Stock-based Compensation Expense Recorded (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureStockbasedCompensationDetailsOfStockbasedCompensationExpenseRecorded Stock-based Compensation - Details of Stock-based Compensation Expense Recorded (Detail) Details 34 false false R35.htm 136 - Disclosure - Net Loss per Share - Common Shares Excluded from the Calculation of Net Loss per Common Share Attributable to Common Stockholders (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureNetLossPerShareCommonSharesExcludedFromTheCalculationOfNetLossPerCommonShareAttributableToCommonStockholders Net Loss per Share - Common Shares Excluded from the Calculation of Net Loss per Common Share Attributable to Common Stockholders (Detail) Details 35 false false R36.htm 137 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation Subsequent Events - Additional Information (Detail) Details 36 false false All Reports Book All Reports rxii-20170930.xml rxii-20170930.xsd rxii-20170930_cal.xml rxii-20170930_def.xml rxii-20170930_lab.xml rxii-20170930_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 52 0001193125-18-096031-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-18-096031-xbrl.zip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�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end

Large accelerated filer

Accelerated filer

Non-accelerated filer

☐ (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company